About Asbestos Mesothelioma

Loryna Blood Clots News – 2/16/2012: Did you take Loryna? Please contact us today if you took Loryna and later experienced harmful side effects. We will connect you with a lawyer that is experienced in complex litigation that may be able to help you recover monetary damages.

Loryna Blood Clots: Although the pathogenic mechanisms are not definite, current models favor direct angiotoxicity involving endothelial and vascular smooth muscle cells, as well as impaired thrombolysis. Testing for homocysteine has not been recom­mended as a component of population screening for cardiovascular disease risk factors. The American Heart Association Nutrition Committee recommended measuring homocysteine levels in ‘‘high-riskpatients with a strong family history for premature atherosclerosis or with arterial occlusive diseases, particularly in the absence of other risk factors, as well as in members of their families’.

Interest in homocysteine levels among diabetics has grown over the past few years. Elevated homocysteine levels do not appear to be more common in type 1 diabet­ics, but a different situation may hold when renal impairment is present. Elevated levels are common in diabetes and are particularly associated with mild increases in serum creatinine and urinary excretion of albumin in type 1 diabetes. Young diabetics who smokehavebeenreported to have higherhomocysteine levels than diabetic nonsmokers. Similarly, the Hoorn Study in the Nether­lands demonstrated very strong associations between elevated homocysteine and death and disease in a nested case-control study that included approximately 800 subjects. In this study, the relative odds for mortality was similar for elevated homocysteine (>14 ^mol/L), hypertension, current smoking, and elevated choles­terol (>200 mg/dL). The authors report emphasized that the homocysteine associ­ations were stronger in diabetic than in nondiabetic participants.

While mean levels of homocysteine are approximately 10 ^mol/L in healthy adults and 14 to 15 ^mol/L in coronary disease cases, higher levels are commonly observed in persons with end-stage renal disease, where levels are typically in the 20 to 30 ^mol/L range. These elevations are often present despite regular use of folate supplementa­tion and demonstration of normal folate levels in the plasma. Recent cross­sectional data from Rhode Island dialysis patients suggest that elevated homo­cysteine levels are present even after folate fortification was instituted, and clini­cal trials of high-dose folate supplementation for renal patients have been suggested as a tactic to prevent atherosclerotic disease in this high-risk patient group.

Loryna Blood Clots News: More information about your search

Loryna Blood Clots: New factors associated with increased risk for coronary heart disease arouse great interest and enthusiasm, kindling the hope that we may enhance identification of individuals at risk for CHD. Important concerns are that such metabolic factors be biologically plausible, measurable, repeatable, strong, graded, and treatable (37-39). Measurement issues include accuracy and precision for the factor in the laboratory and evidence of low or modest variability in the clinical setting. If the laboratory or biological variability is very large, the utility of the measurement for predictive purposes is seriously reduced.

Many years of experience and stan­dardization of measurements are available for some vascular risk factors, and less experience is available for homocysteine. New risk factors may provide clues to pathogenesis and in some instances may improve our ability to predict disease. The ability to predict new vascular disease events should be demonstrated after consideration of the core set of factors that are currently available, including age, sex, blood pressure, cholesterol or LDL cholesterol, HDL cholesterol, smoking, and diabetes mellitus. This criterion is often not met in new investigations and considerable experience and relatively large data sets and follow-up may be nec­essary to assure that new factors, such as homocysteine, prove useful in predicting vascular disease risk.

Elevated homocysteine levels may be accompanied by decreased blood levels and intake of folate, vitamin B₆, or vitamin B₁₂. These vitamins are important cofactors in the metabolism of homocysteine, and border­line deficiencies are relatively common, affecting approximately 30% of the el­derly participants in the Framingham Heart Study. Greater intake of these vitamins in the diet, with supplements in the form of multivitamins, or through fortification of foods, has led to less vitamin deficiency and a decrease in the prevalence of elevated homocysteine levels. Fortification of the food supply in the United States with folate was announced in early 1996 with a mandated enactment date of January 1, 1998. Analyses of homocysteine and folate levels before and after fortification have been undertaken in Framingham Heart Study participants and showed a dramatic decline in the prevalence of low folate levels, a reduction in the prevalence of elevated homocysteine from approximately 20 to 10%, and a modest decrease in mean homocysteine levels from approximately 10 to 9 |J.mol/L.

Antiphospholipid antibodies (APLA) are a heterogeneous group of autoantibod­ies associated with both arterial and venous thrombosis, recurrent pregnancy loss, and thrombocytopenia. They can occur either in association with other auto­immune conditions, most frequently systemic lupus erythematosus (SLE), or in isolation, a condition known as the primary antiphospholipid antibody syndrome. In the research laboratory, many antiphospholipid antibodies (with varying epi­tope specificity) can be identified. However, in clinical practice, the antiphospho­lipid antibodies are divided into two large groups, the lupus anticoagulants and the anticardiolipin antibodies.

Loryna Blood Clots News: Additional Information and Resources

Loryna Blood Clots: Lupus anticoagulants or nonspecific inhibitors interfere with the assembly of procoagulant complexes. In vitro, these antibodies are associated with the pro­longation of phospholipid-dependent blood-clotting times. Characteristically, clotting times return to normal with the addition of exogenous phospholipid. Lu­pus anticoagulants may demonstrate specificity for blood-clotting proteins, in particular prothrombin. However, the mechanism by which they promote throm­bosis is unknown. Lupus anticoagulants are likely associated with a high risk of first and recurrent thrombosis as well as recurrent pregnancy loss.

APLA are found in about 20% of patients presenting with venous thromboembo­lism, in about 10% of patients presenting with first ischemic stroke, and in approximately 5 to 10% of young people presenting with first myocardial infarction. Their prevalence in the unselected population is unknown; reported rates vary widely with the test system used and the population being studied. About 30% of individuals with systemic lupus erythematosus have an APLA. Low-titer anticardiolipin antibodies are frequently detected in otherwise well individuals; repeat testing reveals a high rate of spontaneous resolution.

Many ACA are specific for beta-2 glycoprotein-1 in concert with cell-surface anionic phospholipid (6) and are detected and quantified using accurate ELISA (7,8). The levels of IgG, IgA, and IgM antiphospholipid antibodies can be quanti­fied and are usually reported in phospholipid antibody units (PL units). The iso­type and subgroup specificity of ACA appears to be important. For example, high-titer IgG ACA is associated with a high risk of clinical complications, while the clinical significance of IgM or IgA ACA, even when present in high titer, is less clear. Anticardiolipin antibody testing is notoriously inaccurate; both within- and between-center reliability is poor.

LAC are a heterogeneous group of autoantibodies, which prolong the clot­ting time in a variety of assays and may demonstrate specificity for beta- 2 glycoprotein-1. LAC do not prolong clotting times in assays in which phospholipid is present in excess. This suggests that LAC inhibit in vitro coagula­tion by interfering with the assembly of procoagulant complexes on phospholipid surfaces. This observation also forms the basis for the test for LAC—a prolonged clotting time, in a phospholipid-limited assay system, that normalizes with the addition of excess phospholipid confirms the presence of LAC. Anecdotal experi­ence suggests that lupus anticoagulants are much less common than anticardio- lipin antibodies, that they are infrequently transient, and that they are associated with a high risk of complications, although none of these observations has been adequately studied. Furthermore, laboratory assays for lupus anticoagulants.­

Loryna Blood Clots News: News and Information from related Sources

Loryna Blood Clots: For the prevention of thromboembolism, high-intensity warfarin (target INR > 2.8) has been evaluated in five settings: patients with tissue heart valves patients with acute deep vein thrombosis; patients with APLA (16,29,30); patients with previous stroke; and patients with coronary artery disease (26). High-intensity warfarin was not more effective than standard-intensity warfarin in the first two studies: these results contrast with those reported in patients with coronary artery disease in whom high-intensity warfarin was associated with a reduced risk of death, myocardial infarction, and stroke at a cost of an increased risk of hemorrhage. In patients with previous stroke, the SPIRIT study demonstrated that, compared with aspirin (80 mg/ day), warfarin administered with a target intensity of 3.0 to 4.5 resulted in a significant increase in the risk of hemorrhage (hazard ratio 2.3; 95% CI, 1.6 to 3.5). The incidence of bleeding increased by a factor of 1.43 (95% CI, 0.96 to 2.13) for each 0.5-unit increase of the achieved INR. A similar increase in the risk of hemorrhage was reported in the other investigations of warfarin adminis­tered with a target intensity of more than 3.0.

The annual risk of fatal, major, and minor bleeding in patients receiving warfarin with a target INR of 2.0 to 3.0 is 0.4% to 1.0%, 1.3% to 6.6%, and 8% to 22%, respectively, rates approximately 5 times those seen in patients not re­ceiving warfarin. The risk of hemorrhage varies with the duration of anticoagulant therapy, with the greatest risk in the first year of therapy. In addition, the major bleeding rate increases in proportion to the INR. Based on many prospective studies, the annual risk of major hemorrhage in a patient treated with long-term warfarin with a target INR of 2.0 to 3.0 is likely to be 3% or less. The risk increases as the INR target range is increased beyond 3.0. Based on a comprehensive review of the literature, Landefeld esti­mated that the risk of hemorrhage increases threefold when the target INR is increased from 2.5 to 3.5, a figure also reported by the SPIRIT investigators. This potential for warfarin resistance explains why most ongoing trials eval­uating long-term, low-dose warfarin regimens (INR 1.5-2.0) have excluded pa­tients with known ACA syndromes.

A congenital or acquired hypercoagulable state should be suspected in all patients presenting with unusual forms of thrombosis or in whom thrombosis occurs at a young age in the absence of identifiable risk factors. Hypercoagulable states associated with venous thrombosis include activated protein C resistance (with or without factor V Leiden), the prothrombin gene 20210A mutation, and defi­ciencies of protein C, protein S, or antithrombin. Hyperhomocysteinemia can be either congenital or acquired and is associated with both arterial and venous thrombosis, as are the antiphospholipid antibodies. Unexpected arterial thrombo­sis in otherwise well patients can be associated with hyperhomocysteinemia or antiphospholipid antibodies.

All patients with unexplained venous thrombosis, in particular those with thrombosis in unusual sites (such as the cerebral veins or mesenteric veins), should be screened for an antiphospholipid antibody. Both a lupus and an anticar- diolipin antibody should be sought. Testing should be carried out in accordance with the recommendations of the International Society of Thrombosis and He- mostasis, with appropriate confirmatory assays for suspected lupus anticoagu­lants. Patients with arterial thrombosis should also be screened for a hypercoag- ulable state if their thrombosis has occurred at a young age, or in an unusual location in the absence of other risk factors such as valvular heart disease. Testing of cholesterol and triglyceride levels, homocysteine levels, preferably in the fast­ing state, and antiphospholipid antibodies may reveal a treatable cause for their episode of arterial thrombosis.

Loryna Blood Clots News: Information and News

Loryna Blood Clots: Many questions remain unanswered in patients with antiphospholipid antibodies. First, many patients, particularly those with systemic lupus erythematosus, are screened for the presence of an antiphospholipid antibody despite their never having had an episode of thrombosis. When detected, the clinical importance of the antibody is unknown. As a result, some such patients (who are suspected to have a high risk of first thrombosis) are treated with warfarin with varying INR target ranges, while others are treated with aspirin or other antiplatelet agents, and many receive no antithrombotic prophylaxis. To address the need for routine antithrombotic prophylaxis in this problematic patient population, a large, ran­domized clinical trial is currently being carried out. Within this study, adults and children, with both an antiphospholipid antibody and systemic lupus erythemato­sus, are allocated to long-term warfarin with a target INR of 2.0, or no therapy. The primary outcome measure of the study is the rate of objectively confirmed arterial and venous thrombosis.

A second frequently encountered clinical problem is determining the opti­mal intensity of warfarin anticoagulation in patients with an APLA and a history of previous thrombosis. Evidence-based treatment recommendations are not available, and there is a large variation in practice habits for patients with this problem. Two large, multicenter trials are currently under way which will address this issue. In both, patients with a persistently positive APLA and a history of arterial or venous thrombosis are allocated to receive warfarin with a target INR that exceeds 3.0 versus lower intensity anticoagulation. These studies will provide guidance for the optimal intensity of warfarin therapy and reliable esti­mates of the risk of recurrent thrombosis in patients treated with warfarin with a target intensity of less than 3.0.

There is a large body of evidence that patients with antiphospholipid antibodies have an increased risk of pregnancy complications, including pregnancy loss (36-38). The pathophysiology of recurrent pregnancy loss in such patients is not completely understood, and current theories revolve around placental pathol­ogy leading to fetal hypoxia. These theories invoke either placental vascular thrombosis leading to placental infarction; abnormal uteroplacental vascular con­version, as in spiral artery vasculopathy; or a combination of the two. In particular, recent interest has focused on changes in cell-surface annexin V in response to antiphospholipid antibodies. Reductions in the levels of annexin V might be associated with the development of a procoagulant state in the uterus.

In an effort to improve the rate of successful pregnancy outcomes, a variety of interventions, including low-dose aspirin (ASA), heparin, prednisone, intrave­nous immunoglobulins, and combinations of these therapies, have been used. It is plausible that antithrombotic therapy (heparin and aspirin) might reduce the risk of pregnancy loss, if this loss is due to placental vascular thrombosis. Prednisone has anti-inflammatory and immunosuppressive properties, which might reduce the risk of fetal loss either by reducing the production of APLA or by reducing placental vascular changes that promote a prothrombotic state. Intravenous immunoglobulin is believed to improve the likelihood of successful pregnancy outcomes in patients with APS by either blocking the activity of autoantibodies (mediated by passively transferred anti-idiotypic anti­bodies) or by immune modulation (up-regulation of suppressor T-cell function); both antibody blockade and immune modulation could theoretically prevent placental thrombosis by reducing the levels of APLA.

Our use of the term or terms Loryna Blood Clots News is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Loryna Blood Clots News visit our site often.

Loryna Blood Clots

Loryna Class Action Lawsuit News – 2/16/2012: Loryna may be linked to serious negative side effects. If you took Loryna and believe you suffered negative side effects as a result, contact us today so that we can make arrangements for a free consultation with a law firm that is investigating cases related to the side effects of Loryna.

Loryna Class Action Lawsuit: An emerging concept of GP IIb/IIIa inhibition, based on evidence from two trials, is that these agents appear to be able to reduce the size of an evolving non-ST-elevation MI, and potentially prevent the development of myocardial ne­crosis. In the troponin substudy of PRISM-PLUS, patients randomized to tiro- fiban plus heparin and aspirin had a significantly lower peak troponin level as compared with patients who received heparin and aspirin alone. This observation was made among patients who had a negative CK-MB on admis­sion. In PURSUIT, using peak CK-MB as a measure of infarct size, it was observed that infarct size, either the index MI or a recurrent MI, was signifi­cantly smaller in patients treated with eptifibatide. Thus, when using these potent antiplatelet therapies early in the course of treatment, there appears to be an immediate reduction of the severity of the presenting illness, which is similar to the beneficial effect of chronic aspirin use in reducing the severity of the pre­senting acute coronary syndrome.

Thrombolytic therapy has dramatically reduced mortality following acute myo­cardial infarction. Its benefit is due to early achievement of infarct-related artery patency, which limits myocardial infarct size, decreases left ventricular dysfunc­tion, and improves survival. While thrombolytic therapy has proved to be a major advance in the treatment of patients with acute myocardial infarction, current regimens are limited by failure of initial reperfusion, inadequate perfusion with delayed flow (TIMI grade 2 flow), reocclusion, and reinfarction in sig­nificant percentages of patients. Because these problems are associated with increased subsequent mortality, and because platelets play a central role in failed reperfusion, reocclusion, and reinfarction, attention has turned to the promising glycoprotein IIb/IIIa inhibitors.

In the setting of ST-elevation MI, IIb/IIIa inhibition was first used following thrombolysis in the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI)-8 trial using abciximab following tissue plasminogen activator (tPA). A consistent dose-dependent inhibition of platelet aggregation was observed and major bleeding was not increased. Eptifibatide was tested in the Integrilin to Manage Platelet Aggregation and Combat Acute Myocardial Infarction (IMPACT-AMI) trial. In addition to accelerated, full-dose tPA, aspirin, and heparin, patients were randomized to ep­tifibatide, at one of six doses, or placebo. The highest dose of eptifibatide ap­peared to improve the 90-min rate of TIMI grade 3 flow (66 vs. 39% for placebo; p = 0.006). More recently, a pilot study combined full-dose streptokinase (1.5 million U/h) and three doses of eptifibatide (180-^g/kg bolus and either 0.75-, 1.33-, or 2.0-^g/kg/min infusion for 24 h) or placebo. Adding the IIb/IIIa inhibitor led to a modest improvement in early complete reperfusion (TIMI grade flow 3 at 90 min) from 38% with placebo to approximately 50% with eptifibatide. The highest dose of eptifibatide was associated with increased bleeding and was discontinued. Further testing of eptifibatide is planned with reduced-dose thrombolytic agents.

The combination of a reduced-dose fibrinolytic agent and a GP IIb/IIIa inhibitor was tested in the TIMI-14 trial, using tPA, streptokinase, and reteplase; in SPEED (Strategies for Patency Enhancement in the Emergency Department) using rete- plase; and in INTRO-AMI and several ongoing trials. In the TIMI-14 trial dose-ranging phase, 681 patients with ST-segment- elevation MI meeting with standard eligibility criteria were randomized within 12 h of onset of chest pain to receive one of four reperfusion regimens (each with several dose levels): accelerated (full-dose) tPA alone (the control arm); reduced-dose tPA plus abciximab; reduced-dose streptokinase plus abciximab; or abciximab alone. All patients received aspirin and heparin, with the initial heparin dosage being 70-U/kg bolus and a 15-U/kg/h infusion in the tPA control arm, and 60-U/kg bolus and a 7-U/kg/h infusion in the abciximab groups.

Loryna Class Action Lawsuit News: Additional Information and Resources

Loryna Class Action Lawsuit: Abciximab alone was associated with a rate of TIMI grade 3 flow at 90 min of 32% and patency rate of 48% (43). The combination of streptokinase and abciximab produced only slight improvement in 90-min TIMI grade 3 flow: 42% in the 0.5-MU group; 39% in the 0.75-MU group; and 47% in the 1.25-MU group. The 1.5-MU regimen plus abciximab was discontinued after four of six patients developed a major hemorrhage, one of whom had an ICH. Of the various dosing regimens of tPA tested, the best angiographic results were obtained using a 50-mg dose given as a 15-mg bolus and a 35-mg infusion over 60 min. The rate of TIMI grade 3 flow at 90 min was 77% compared with 62% for tPA alone (p = 0.02). Overall patency was achieved in 93% of patients with the combination of abciximab and half-dose tPA compared with 78% for full-dose tPA alone (p = 0.09). An even greater difference was observed at 60 min: accelerated tPA achieved only 43% TIMI grade 3 flow at 60 min compared with 72% for 50-mg tPA plus abciximab (p = 0.0009). Major hemorrhage was similar (approximately 6%) among the tPA plus abciximab and control groups. In-hospital mortality was low in all groups, ranging from 3 to 5%.

The Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI)-16 trial tested the oral Il/IIIa inhibitor, orbofiban, in patients with acute coronary syndromes. This trial enrolled 10,288 patients at 888 hospitals in 28 countries. The inclusion criteria were onset of an acute coronary syndromes within 72 h, defined as an episode of rest ischemic pain lasting at least 5 min associated with either positive cardiac enzymes (i.e., an acute MI), ECG changes, or a prior his­tory of coronary or vascular disease. Exclusion criteria included renal insuffi­ciency (creatinine >1.6 mg/dL, increased high bleeding risk, or need for oral anticoagulation. All patients received 150 to 162 mg of ASA daily and were randomized, in double-blind fashion, to one of two doses of orbofiban or placebo. In one group, orbofiban was administered as 50 mg twice daily throughout the trial (50/ 50 group); in the other group, 50 mg was given twice daily for the first 30 days (the highest risk period), and was reduced to 30 mg twice daily for the remainder of the trial (50/30 group). Other treatments were at the discretion of the pa­tient’s physician. The primary endpoint was a composite of death, MI, recurrent ischemia leading to rehospitalization or urgent revascularization, or stroke. The planned sample size was 12,000 patients, but the trial was terminated early after an unexpected finding of increased mortality at 30 days in one of the orbofiban groups.

Mortality through 10 months was 3.7% for the placebo group versus 5.1% in the 50/30 group (p = 0.008) and 4.5% in the 50/50 group (p = 0.11). There were no differences in the primary composite endpoint at 10 months (22.9, 23.1, and 22.8%, for the placebo, 50/30, and 50/50 groups, respectively). Major or severe bleeding (but not intracranial hemorrhage) was higher with orbofiban; it occurred in 2.0, 3.7 (p = 0.0004), and 4.5% (p < 0.0001) of patients, respec­tively. Exploratory subgroup analyses did identify that patients who underwent percutaneous coronary intervention had a lower mortality and a significant reduc­tion in the composite endpoint (p = 0.001) with orbofiban. Two substudies from OPUS-TIMI-16 found that orbofiban led to increases in measures of platelet activation, notably P-selectin. These data are con­sistent with observations of other agents, which induced an apparent prothrom- botic effect, with increases in measures of platelet activation and increases in platelet aggregation when drug levels were low. Interestingly, in the TIMI-12 trial, no increase in P-selectin was observed with sibrafiban therapy. Active research is ongoing, but these initial studies suggest that there may be differences among the various oral IIb/IIIa inhibitors with regard to potential prothrombotic effects.

The Evaluation of oral Xemilofiban in Controlling Thrombotic Events (EXCITE) trial studied xemilofiban in 7232 patients undergoing PCI with either stenting or balloon angioplasty without adjunctive intravenous IIb/IIIa inhibition. Patients were randomized in a double-blind fashion to receive one of two doses of xemilofiban or placebo: All the xemilofiban patients received a first 20-mg dose 30 to 90 min prior to PCI, followed by either 10 or 20 mg three times daily for 6 months. The primary endpoint—death, MI, or urgent revascularization at 6 months—occurred in 13.6% of patients in the placebo group, 14.1% of patients in the xemilofiban 10-mg group, and 12.6% of patients in the xemilofiban 20­mg group (p = NS) (78). There was a trend toward fewer periprocedural MIs over the first 48 h following PCI, but this benefit was not sustained at 30 days or 6 months. Mortality at 6 months was 1.0% for placebo, 1.6% for the 10­mg xemilofiban dose group, and 1.1% in the 20-mg dose group. Major bleed­ing was significantly more common in the xemilofiban-treated patients. Thus, xemilofiban did not significantly reduce cardiac events in this patient popu­lation.

Loryna Class Action Lawsuit News: News and Information from related Sources

Loryna Class Action Lawsuit: The second Symphony trial was terminated prematurely at the time the results from the first Symphony trial were available (and not due to safety issues). It compared the combination of low-dose sibrafiban plus aspirin vs. high-dose si­brafiban (without aspirin) vs. aspirin alone in 6671 patients with stabilized acute coronary syndromes. With an average follow-up of 90 days, the primary endpoint, death, MI, or severe recurrent ischemia, was not different among the three groups: 10.5% in the high-dose sibrafiban group; 9.2% for low-dose sibrafiban plus aspi­rin vs. 9.3% for aspirin alone. In this trial (but not in the larger first Symphony trial), mortality was significantly higher with the high-dose sibrafiban group: 2.4 vs. 1.7% for the low-dose sibrafiban plus aspirin group vs. 1.3% for placebo. Recurrent MI followed a similar pattern: 6.9% for high-dose sibrafiban, 5.3% for the low-dose plus aspirin group, and 5.3% for aspirin. Major bleeding was more common with high-dose sibrafiban (4.6%), and higher still for the combination of low-dose sibrafiban plus aspirin (5.7%) vs. 4.0% for aspirin alone.

It is an exciting time for the practicing physician given the availability of this important new therapy that can significantly reduce death, MI, or refractory ischemia/urgent revascularization. The benefits apply to essentially all patients undergoing PCI, thereby becoming a new standard of care in this setting. For the huge number of patients with unstable angina and non-ST-elevation MI, IIb/ IIIa inhibition will significantly reduce recurrent ischemic events. The trials to date have targeted the higher risk unstable angina patients—those with ECG changes or positive cardiac enzymes, and thus these are the patients in clinical practice who should be targeted for early use of IIb/IIIa inhibitors.

Platelets are integrally involved in the thrombotic complications of atherosclero­sis. Their contribution to thrombosis complicating a ruptured atherosclerotic plaque is well established. Interference with platelet function, therefore, should help to prevent thrombotic occlusion of arteries affected by atherosclerosis. In­deed, numerous studies have demonstrated that antiplatelet agents decrease ad­verse cardiovascular events in patients with atherosclerosis. This chapter will focus on three such antiplatelet agents: aspirin, ticlopidine, and clopidogrel. It will include a brief review of platelet function followed by a discussion of the mechanisms of action of these antiplatelet drugs. Thereafter, clinical evidence supporting the notion that antiplatelet agents reduce adverse cardiovascular events in patients with atherosclerosis will be presented.

The three principal events in the formation of a platelet plug include platelet adhesion, activation, and aggregation. Platelets normally circulate in an inacti­vated state. Vascular injury and disruption of the endothelial lining initiates the process of platelet adhesion, in which platelets are deposited on the intimal surface of blood vessels. Among the most important substances to mediate platelet adhesion to the vascular surface is von Willebrand factor. It binds suben­dothelial collagen to the platelet glycoprotein Ib-IX-V receptor. Binding of plate­lets to the vascular surface prompts an intracellular signaling mechanism, includ­ing the metabolism of arachidonic acid to thromboxane A₂. In addition, the platelets release constituents of their alpha and dense granules such as p-selectin.

Loryna Class Action Lawsuit News: Information and News

Loryna Class Action Lawsuit: Aspirin inhibits arachidonic acid metabolism and prevents the formation of thromboxane A₂ by irreversibly inhibiting cyclooxygenase via acetylation of a serine moiety. Platelet inhibition occurs approximately 60 min following the oral ingestion of aspirin. The inhibitory effects of platelets last the life of a platelet, which is approximately 10 days. Hemostatic recovery following a single dose of aspirin occurs as new platelets are formed and enter the circulation. Both ticlopidine and clopidogrel are thienopyridines. These inhibit the function of platelet ADP receptors and thereby limit conformational changes in the glycoprotein IIb/IIIa receptor. Inhibition of platelet aggregation occurs ap­proximately 1 to 2 days following administration of these drugs, and 40 to 60% inhibition of ADP-induced aggregation is observed 3 to 5 days following inges­tion. Platelet function is restored approximately 3 to 4 days after discontinua­tion of ticlopidine or clopidogrel.

The beneficial effects of aspirin on cardiovascular outcome in patients with ath­erosclerosis is well established. The Antiplatelet Trialists’ Collaboration per­formed a metanalysis of over 73,000 patients with clinical manifestations of ath­erosclerosis such as acute myocardial infarction, prior myocardial infarction, or prior stroke or transient ischemic attack, in which patients were treated with either antiplatelet therapy or a control. The most widely studied antiplatelet drug was aspirin. Overall, antiplatelet therapy was associated with a 25% odds reduc­tion for the aggregate endpoint of stroke, myocardial infarction, or vascular death. The studies included in this metanalysis, as well as some more recent studies, highlight the efficacy of aspirin in reducing cardiovascular morbidity and mortality in patients with atherosclerosis. Some of the larger studies involving patients with coronary artery disease, cerebrovascular disease, or peripheral arte­rial disease are described below.

In the Antiplatelet Trialists’ Collaboration, antiplatelet therapy, primarily aspirin, was associated with a 29% odds reduction for stroke, myocardial, or vascular death among approximately 20,000 patients with acute myocardial infarction and a 25% odds reduction for these adverse events among approximately 20,000 pa­tients with prior myocardial infarction. The largest trial for acute myocardial infarction included in the Antiplatelet Trialists’ Collaboration was the Second International Study of Infarct Survival (ISIS-2), which randomized over 17,000 patients with acute myocardial infarction to aspirin, streptokinase, both, or neither. Compared to placebo, aspirin was associated with a 23% risk reduction for vascular death, a 50% reduction for nonfatal reinfarction, and a 46% reduction for nonfatal stroke 5 weeks after randomization. The combination of streptokinase and aspirin was more effective than either agent alone in reducing vascular death. The efficacy of aspirin in preventing coronary reocclusion follow­ing thrombolysis for acute myocardial infarction is supported by a metanalysis of 32 studies. Reocclusion occurred in 11% of 419 patients treated with aspirin versus 25% of 513 patients not treated with aspirin, and recurrent ischemic events occurred in 25% of 2977 patients treated with aspirin compared to 41% of 721 patients who were not treated with aspirin.

Several large trials have demonstrated the efficacy of aspirin in preventing myocardial infarction and death in patients with unstable angina. A Veterans Administration Cooperative study randomized 1256 men with unstable angina to aspirin or placebo for 12 weeks. The incidence of fatal or nonfatal myocardial infarction was reduced by 51% in the group treated with aspirin compared to the group treated with placebo. A Canadian multicenter trial randomized 555 patients with unstable angina to aspirin, sulfinpyrizone, both, or neither to 24 months of treatment. The incidence of fatal or nonfatal myocardial infarction was 8.6% in the groups receiving aspirin compared to 17% in the groups not receiving aspirin, resulting in a 51% risk reduction with aspirin. Theroux et al. compared the efficacy of aspirin, intravenous heparin, both, or neither in 479 patients with unstable angina. Approximately 6 days following randomization, myocardial infarction had occurred in 11.9% of patients who received neither aspirin nor heparin, in 3.3% who received any aspirin, in 0.8% of those who received only heparin, and in 1.6% of patients who received both aspirin and heparin. The Research Group on Instability in Coronary Artery Disease in Southeast Sweden (R.I.S.C.) randomized 796 men with unstable angina or non-Q-wave myocardial infarction to aspirin or placebo. After 1 year, myocardial infarction occurred in 21.4% of patients treated with placebo and in 11% of patients treated with aspirin. Thus, aspirin treatment reduced the risk of nonfatal or fatal myocardial infarction by 48%.

Our use of the term or terms Loryna Class Action Lawsuit is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Loryna Class Action Lawsuit News visit our site often.

Loryna Class Action Lawsuit

Loryna Class Action News – 2/16/2012: If you were prescribed Loryna and have suffered negative side effects, please contact us today so that we can put you in touch with an attorney to advise you of your legal rights.

Loryna Class Action: The findings from the observational studies that hormone users are at generally lower risk from coronary disease do not necessarily imply cause and effect. Women and their physicians decide on estrogen therapy. Often the health status of the woman will have an important influence on this decision and on the results of studies that examine these women. Thus, some have argued that hormone use is merely a marker rather than a cause of good health. Most of the observational studies reviewed here have provided some in­formation bearing on this critical point. The Nurses’ Health Study tried to evalu­ate whether increased medical care of women using postmenopausal hormones might be responsible for the benefit observed. In an analysis limited to women who reported regular physician visits (50% of the cohort), results were sim­ilar to those found in the larger population of all subjects: the relative risk for major coronary heart disease was 0.52 (95% CI, 0.37-0.74) for current hormone use.

Another approach is to examine the risk profile of estrogen users and non­users to determine whether the differences, if any, are sufficient to explain the large decrease in risk among estrogen users. Barrett-Connor observed that, in a cohort of postmenopausal women, those taking estrogens reported more in­tensive health-care behavior, including frequent screening tests such as blood cholesterol measurement and mammograms. An examination of determinants of estrogen therapy in 9704 women participating in a large, multicenter study of osteoporotic fractures found that hormone users tended to be better educated, less obese, and drank alcohol and participated in sports more often than nonusers. Similarly, in a prospective study of randomly selected premenopausal women, observed a better cardiovascular risk factor profile prior to hormone use among the women who subsequently took hormones at menopause than among women who did not.

For hormone users compared to nonusers and, after further adjustment for high blood pressure, history of angina, MI, or stroke, alcohol use, smoking, body mass index, and age at menopause, the relative risk was virtually the same (RR = 0.79; 95% CI, 0.71-0.88), implying an equivalent risk status for users and nonusers. In addition, to further examine this issue, the Nurses’ Health Study conducted an analysis limited to a subgroup of low-risk women (i.e., those with no diagnosis of hypertension, diabetes, or high serum cholesterol who were nonsmokers and had a Quetelet’s Index below 32 kg/m²). Even with such restrictions, the relative risk for coronary disease was almost 40% lower for current hormone users. In summary, to explain the overall benefit of hormone therapy as a result of con­founding by health status, one would have to presume unknown risk factors which are extremely strong predictors of CHD and very closely associated with estrogen use.

LMWHs, like UFH, bind a cofactor called antithrombin to produce their predominant anticoagulant effect. Binding is mediated through a unique pentasac­charide sequence of the mucopolysaccharide that increases by 1000-fold both the interaction between antithrombin and thrombin (factor II_a), and the interaction between antithrombin and factor Xa. However, a minimum chain length of 15 to 18 saccharides (corresponding to a molecular weight of > 5400 daltons) is required to inactivate thrombin. In contrast, inhibition of factor Xa can occur with short polysaccharide chains. Thus, one potentially important distinc­tion between UFH and LMWH, and among LMWHs themselves, is the varying ratio of factor Xa to factor IIa. The factor Xa:IIa activity for UFH is approxi­mately 1.2, while ratios for the various LMWH preparations vary from 2 to 4. Table 1 lists LMWHs in order of anti Xa:IIa ratio.

Loryna Class Action News: Additional Information and Resources

Loryna Class Action: The ESSENCE study was a double-blind, placebo-controlled trial that ran­domly assigned 3171 patients with angina at rest or non-Q-wave myocardial in­farction to receive 2 to 8 days therapy with either 1 mg/kg of enoxaparin subcuta­neously twice daily or continuous intravenous UFH. At 14 days, the risk of death, myocardial infarction, or recurrent angina was significantly lower in the patients assigned to enoxaparin than in those assigned to UFH (16.6% vs. 19.8%; p = 0.019). At 30 days, the risk of this composite endpoint remained significantly lower in the enoxaparin group (19.8% vs. 23.3%; p = 0.016). The need for revas­cularization procedures at 30 days was also significantly less frequent in the pa­tients assigned to enoxaparin (27.1% vs. 32.2%; p = 0.001). The 30-day inci­dence of major bleeding complications was 6.5% in the enoxaparin group and 7.0% in the unfractionated-heparin group, but the incidence of bleeding overall was significantly higher in the enoxaparin group (18.4% vs. 14.2%; p = 0.001), primarily because of ecchymoses at injection sites. Thus, the ESSENCE trial indicates that enoxaparin plus aspirin is more effective than UFH plus aspirin in reducing the incidence of ischemic events in patients with unstable angina or non-Q-wave myocardial infarction in the early phase. This benefit was associated with an increase in minor, but not major, bleeding.

In TIMI-11B, 3910 patients with unstable angina or non-Q-wave MI were randomized to either intravenous UFH for 3 to 8 days followed by subcutaneous placebo injections, or enoxaparin during both the acute phase (initial 30-mg IV bolus followed by injections of 1.0 mg/kg every 12 h for 3 to 8 days) and outpa­tient phase (injections every 12 h for up to 43 days of 40 mg for patients weighing >65 kg and 60 mg for those weighing <65 kg). The primary endpoint (death, myocardial infarction, or urgent revascularization) occurred by 8 days in 14.5% of patients in the UFH group and 12.4% of patients in the enoxaparin group (OR 0.83 [0.69 to 1.00]; p = 0.048) and by 43 days in 19.7% of the UFH group and 17.3% of the enoxaparin group (OR 0.85 [0.72 to 1.00]; p = 0.048). During the first 72 h and also throughout the entire initial hospitalization, there was no differ­ence in the rate of major hemorrhage in the treatment groups. During the outpa­tient phase, major hemorrhage occurred in 1.5% of the group treated with placebo and 2.9% of the group treated with enoxaparin (p = 0.021). Consistent with the ESSENCE findings described above, the results of the TIMI-11B study demon­strate that enoxaparin is superior to UFH in reducing a composite of death and serious cardiac ischemic events during the acute management of patients present­ing with unstable angina, but does not cause a significant increase in the rate of major hemorrhage.

Last, the FRAXIS trial (29) randomized 3468 patients in a double-blind fashion to one of three treatment regimens: UFH (5000 IU bolus, followed by an infusion for 6 ± 2 days); nadroparin for 6 days (nadroparin 86 anti-Xa IU/kg IV bolus, followed by twice-daily subcutaneous injections for 6 ± 2 days); or nadroparin for 14 days (same dose as the prior group for 14 days). No statistically significant differences were observed among the three treatment regimens with respect to the primary outcome (cardiac death, myocardial infarction, refractory angina, or recurrence of unstable angina at day 14). The absolute differences between the groups in the incidence of the primary outcome were: -0.3% (p = 0.85) for the nadroparin 6-day group vs. the UFH group, and +1.9% (p = 0.24) for the nadro- parin 14-day group vs. the unfractionated heparin group. Furthermore, there were no significant intergroup differences regarding any of the secondary efficacy out­comes. However, there was an increased risk of major hemorrhage in the nadro­parin 14-day group compared with UFH (3.5% vs. 1.6%; p = 0.0035). Thus, similar to the FRISC-I trial findings with dalteparin, treatment with nadroparin for 6 days provides similar efficacy and safety to treatment with UFH for the same period. A prolonged regimen of nadroparin (14 days) does not provide any additional clinical benefit and is associated with an increase risk of major hemorrhage.

The use of LMWH as an adjunct to fibrinolytic therapy is actively under investi­gation (33-37). Preliminary results from the HART-II angiographic study (37) demonstrated slightly higher rates of infarct artery patency (80.1% vs. 75.1%; p = NS) and TIMI grade 3 flow rates (52.9% vs. 47.6%; p = NS) at 90 min among 200 patients receiving tPA and enoxaparin (30 mg IV bolus followed by 1 mg/ kg SQ twice daily for >72 h) compared to tPA and UFH. Clinical event rates were similar and reocclusion among patients with a patent artery at 90 min tended to be less frequent in those randomized to enoxaparin (5.9 vs. 9.8%; p = NS). In another angiographic study (36), dalteparin was compared with placebo in patients receiving streptokinase. TIMI grade 3 flow 20 to 28 h later tended to be higher in patients treated with dalteparin (68% vs. 51%; p = 0.10) and the number of ischemic episodes on continuous ECG monitoring was lower (16% vs. 38%; p = 0.04).

Loryna Class Action News: News and Information from related Sources

Loryna Class Action: Direct thrombin inhibitors, as indicated by the class name, do not require anti­thrombin or another cofactor to inhibit the function of thrombin. Direct thrombin inhibitors inhibit all the major actions of thrombin, including thrombin-induced generation of fibrin, thrombin-induced platelet activation, as well as thrombin’s autocatalytic reaction. Potential advantages of direct thrombin inhibitors over heparin include: inhibition of clot-bound thrombin lack of inhi­bition by activated platelets; and stable anticoagulant response since no cofactor is required. The prototypic direct thrombin inhibitor is hirudin, a polypeptide consisting of 65 amino acids derived from the leech Hirudo medicinalis. Hirudin selec­tively binds thrombin in a 1:1 fashion at two locations: the carboxy terminus of hirudin binds to the substrate recognition site, the domain of thrombin that recognizes fibrinogen or the platelet and the amino terminus of hirudin binds to the catalytic site of thrombin. Hirudin does not inhibit factor Xa, IX, kallikrein, activated protein C, plasmin, tissue plasminogen activator, or other enzymes in the coagulation or fibrinolytic pathways. Although hirudin does not bind covalently to thrombin, the dissociation rate is extremely slow; thus, hirudin essentially irreversibly inhibits thrombin.

Lepirudin was compared to heparin in the OASIS-2 trial (56). While there were trends toward a reduction in cardiovascular death or MI at 72 h (2.0% vs. 2.6%; p = 0.04) and at 7 days (3.6% vs. 4.2%;p = 0.08), there was an attenuation of this benefit by day 35, in contrast to the sustained superiority of enoxaparin over UFH (30). Furthermore, major bleeding requiring transfusion was more fre­quent with lepirudin (1.2% vs. 0.7% for heparin; p = 0.01). The authors per­formed a metanalysis of all the hirudin trials and observed a modest 10% benefit favoring hirudin, although this was not statistically significant for patients with unstable angina/non-ST-elevation MI at 35 days. The Food and Drug Ad­ministration (FDA) recently reviewed the available clinical data and did not ap­prove hirudin for use in unstable angina/non-ST-elevation MI, citing the lack of sustained benefit and increased risk of bleeding.

In the HIT-3 trial, excess intracranial hemorrhage was observed with lepirudin (0.4 mg/kg bolus, 0.15 mg/kg/h infusion) compared to UFH (3.4% vs. 0%) among 302 patients receiving tPA. In the subsequent HIT-4 trial (71), involv­ing 1208 patients and using a lower dose of lepirudin (0.2 mg/kg bolus, 0.5 mg/ kg subcutaneously b.i.d.) in combination with streptokinase, TIMI flow grade 3 was observed in 40.7% in the lepirudin and in 33.5% in the heparin group (p = 0.16). No difference were seen between lepirudin and heparin in the rate of hemorrhagic stroke (0.2% vs. 0.3%), reinfarction (4.6% vs. 5.1%), or mortality (6.8% vs. 6.4%) at 30 days. Thus, intravenous lepirudin (as administered in HIT- 3) as an adjunct to tPA appears to be unsafe, and lower dose lepirudin in combina­tion with streptokinase does not significantly improve reperfusion or clinical out­comes.

Angiographic trials with other direct thrombin inhibitors in conjunction with fibrinolytic therapy have also been conducted. In a pilot study and the HERO trial, a trend toward improved early (90 to 120 min) TIMI grade 3 flow was observed with the higher dose of Hirulog as compared with heparin in patients receiving streptokinase. Testing with other agents found modest or no improvements compared with heparin. HERO-II, an international phase III trial of approximately 17,000 patients with ST-elevation MI treated with strep­tokinase, is randomizing patients to either Hirulog or UFH and should complete enrollment in the latter half of 2000.

Loryna Class Action News: Information and News

Loryna Class Action: Despite tremendous initial enthusiasm for the direct thrombin inhibitors, their current role in clinical practice is limited to use as an anticoagulant in patients with heparin allergy, or in the treatment of heparin-induced thrombocytopenia and thrombotic syndrome. Ongoing and future research, particularly as adjunctive therapy in patients receiving fibrinolysis or percutaneous coronary intervention, may identify other clinical situations in which these drugs could play a useful role. However, studies to date have identified a narrow therapeutic window, mar­ginal evidence of incremental, sustained efficacy over UFH, and the possibility of a ‘‘rebound’’ effect. These problems represent challenges to this class of anti­thrombotic drugs.

Because approximately 4 million patients each year are admitted to hospitals worldwide with unstable angina or acute myocardial infarction (MI), and nearly 1 million patients annually worldwide undergo percutaneous coronary intervention (PCI), physicians have focused a great deal of attention on developing new treat­ments for these acute coronary syndromes (ACS). The initiating event of these acute coronary syndromes is rupture of an atherosclerotic plaque followed by local thrombosis. Similar pathophysiology is present during PCI, which is essen­tially a ‘‘planned’’ plaque disruption.

The peptide and peptidomimetic inhibitors (e.g., tirofiban and eptifibatide) are competitive inhibitors of the IIb/IIIa receptor, with very rapid half-lives of dissociation from the IIb/IIIa receptor (10-20 s). Thus, the level of plate­let inhibition is directly related to the drug level in the blood. Since both inhibitors have short half-lives, when the drug infusion is stopped the antiplatelet activity reverses after a few hours, which is a potential benefit for avoiding bleed­ing complications. The third group of GP IIb/IIIa inhibitors are the oral agents. Within this group, there are also the two broad types of agents, those that are competitive inhibitors, and those that bind tightly to the receptor. The oral drugs are usually prodrugs, which are absorbed and then converted to active compounds in the blood. The oral agents all have longer half-lives, such that they can be given once, twice, or three times daily in order to achieve relatively steady levels of IIb/IIIa inhibition.

Abciximab was also found to be beneficial when started 24 h prior to a PCI in the c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) trial: death, MI, or urgent revascularization was reduced by abcix­imab from 15.9 to 11.3% (p = 0.012) (27). In the Evaluation of IIb/IIIa inhib­itor for Stenting (EPISTENT) trial (28), compared with stenting with only aspirin and heparin, the rate of death, MI, or urgent revascularization at 30 days was significantly reduced in both abciximab groups—from 10.8 to 5.3% for stent plus abciximab (p < 0.001) and 6.9% for balloon angioplasty with abciximab (p = 0.007) (28). Benefits were maintained at 6 month and 1 year, with a significant reduction in 1 year mortality in patients treated with stent plus abcix- imab compared with stent alone. In addition, a metanalysis of abciximab trials has shown that there is a significant reduction in mortality when GP IIb/ IIIa inhibition is used.

Our use of the term or terms Loryna Class Action News is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Loryna Class Action News visit our site often.

Loryna Class Action

Loryna Lawyer News: Please contact us today if you took Loryna and suffered unusual side effects or other injuries.

Loryna Lawsuit: Clinical evidence demonstrating anti-inflammatory and plaque-stabilizing effects of statin drugs has only recently become available. The first study to address whether patients with evidence of inflammation benefited from statin therapy was performed within the Cholesterol and Recurrent Events (CARE) trial, a secondary-prevention evaluation of pravastatin. Consistent with studies of primary prevention, participants in the CARE trial with elevated CRP levels were found to have higher risks of recurrent coronary events than those with lower levels of CRP. However, a clinically apparent interaction between statin therapy and inflammation was also observed in that the proportion of recurrent events prevented by pravastatin was 54% among those with inflammation com­pared with 25% among those without inflammation. Moreover, long-term therapy with pravastatin significantly reduced plasma levels of CRP in a manner that was not related to this agent’s effects on LDL cholesterol. In fact, in this hypothesis-generating study, there was no relationship between the change in CRP and the change in LDL cholesterol at the end of the 5-year follow-up period. Thus, these initial data provided clinical evidence that statin therapy may well have anti-inflammatory properties. While the mechanism of this effect is uncertain, the CARE data provide evidence for possible clinical relevance of laboratory observations demonstrating nonlipid effects of the HMG-CoA reductase inhibitors, such as modulation of immune function, antiproliferative effects on vascular smooth muscle, and antithrombotic properties, as well as morphological ef­fects.

Two major studies have now addressed the validity and clinical importance of these observations. The first, the Pravastatin Inflammation/CRP Evaluation (PRINCE) trial, was explicitly designed to address three questions. First, can the effects of pravastatin on CRP observed in the CARE trial be confirmed in a direct hypothesis-testing setting? Second, how quickly does any effect of pravastatin on CRP occur and are the effects of pravastatin on CRP truly inde­pendent of changes in LDLC? And third, are the effects of pravastatin on CRP observed in CARE (a secondary-prevention study) equally present in primary- prevention populations? In total, the PRINCE trial evaluated 2884 patients: 1182 in a secondary- prevention cohort who received pravastatin 40 mg daily, and 1702 in a primary- prevention cohort randomly allocated to either pravastatin 40 mg daily or placebo. Prior use of lipid-lowering therapy within the previous 6 months was not allowed, and those in the primary-prevention arm had to have LDL choles­terol levels greater than 130 mg/dL. Blood samples were collected at baseline.

As ensured by the randomization process, baseline levels of CRP (median 0.20 mg/dL), total cholesterol (231 mg/dL), LDL cholesterol (143 mg/dL), and HDL cholesterol (40 mg/dL) were virtually identical in the two primary- prevention arms of the PRINCE trial. In contrast, compared with those in the primary-prevention cohort, those with a prior history of cardiovascular disease who were enrolled in the secondary-prevention cohort of PRINCE had signifi­cantly increased CRP levels (median 0.26 mg/dL). As would be expected, those in the secondary-prevention cohort were also older and more likely to smoke or have diabetes, and the group had a higher proportion of aspirin users than the primary-prevention cohort. During the course of the study, highly significant re­ductions in total cholesterol, LDL cholesterol, and triglycerides were observed in the pravastatin groups, as was a clinically important increase in HDL choles­terol (all p values <0.001). No change was observed in any of these parameters among those allocated to placebo.

Loryna Lawyer News: More information about your search

Loryna Lawyer: The main analyses of PRINCE were the effects of statin therapy at both 12 and 24 weeks. In the primary-prevention cohort, pravastatin reduced median CRP levels by 16.9% compared with placebo at the end of the 24-week study period (p < 0.001). This effect was present at 12 weeks (median reduction in CRP with pravastatin 14.7%; p < 0.001). As shown in Figure 7, these effects were observed in all the PRINCE prespecified subgroups, including analyses stratified by age, smoking status, gender, obesity, and lipid levels. As had been hypothesized, virtually no association was observed between CRP and lipid levels either at the study beginning or during follow-up. In fact, in correlational analy­ses, less than 2% of the variance in the change in CRP could be explained by the change in any lipid parameter. Virtually identical effects were also seen in those in the secondary-prevention cohort of the study.

Several decades ago, homocystinuria, a rare pediatric condition, was noted to be associated with musculoskeletal abnormalities and the development of ven­ous thromboembolism and arterial disease in adolescence. The underlying metabolic defect for this condition was shown to be decreased enzymatic activ­ity of cystathionine beta-synthase. This deficiency was associated with in­creased levels of methionine and homocysteine and a decrease in blood levels of cysteine. Later investigations of a patient with elevated homocysteine levels and similar clinical findings, but with a low concentration of methionine in the plasma and evidence of abnormal vitamin B₁₂ metabolism, led to the conclusion that another defect could account for elevated homocysteine levels and vascular disease.

A large variety of factors have been associated with increased levels of homocys­teine, and only the key topics in healthy outpatients will be considered here. Fasting blood homocysteine concentrations are typically greater in the elderly compared with middle-aged adults, and higher in men than in women. Analyses of the Framingham Heart Study and the National Health and Nutrition Examination Survey data have shown that the prevalence of elevated homocyste­ine (>14 |j.mol/L) increases with age in both sexes, and plasma homocysteine levels are inversely correlated with vitamin intake. Vitamins Bj, B₂, B₆, B₁₂, folate, niacin, retinol, vitamin C, and vitamin E have all been studied, but the greatest interest has been shown for vitamins B₆, B₁₂, and folate, as these nutrients act as cofactors for several homocysteine metabolic pathways.

Low vitamin B₁₂ status can also account for elevated homocysteine levels, as this vitamin is a necessary cofactor in several homocysteine metabolic steps. Inadequate production of intrinsic factor in the stomach can result in a severe vitamin B₁₂ deficiency, with substantially elevated homocysteine concentrations, but this etiology is an infrequent cause of low vitamin B₁₂ status. Hypochlorhydria and achlorhydria are more common than inadequate intrinsic factor deficiency, especially in older individuals, and can lead to impaired absorption of vitamin B₁₂ because low pH is needed to dissociate B₁₂ from food.

Loryna Lawyer News: News and Information

Loryna Lawyer: There are many genetic causes of elevated homocysteine levels. Enzymatic de­fects and variants have been associated with cystathionine beta-synthetase, meth­ylene tetrahydrofolate reductase (MTHFR), thermolabile and nonthermolabile variants, and methionine synthetase, to name a few. The MTHFR variant 677- C ^ T has gotten the most attention, as it is relatively common and affects 10 to 15% of North Americans and 5 to 25% of Europeans. This MTHFR variant has also been studied for associations with cardiovascular disease, and homo­zygosity has generally been associated with an increased occurrence of disease; however, several studies demonstrated no association between the MTHFR and vascular outcomes. A meta-analysis concluded that a modest association with increased risk for cardiovascular disease was present. The inconsistent asso­ciation between MTHFR variants and vascular disease may be partially explained by population dietary data. Persons homozygous for MTHFR 677-C ^ T and who had suboptimal folate status were especially likely to have elevated homo­cysteine levels.

Other studies have not always corroborated these results. In some instances, the associations with adverse outcomes were demonstrated for nutrient status, but not for homocysteine levels. For instance, higher homocysteine levels were not associated with greater risk in a MRFIT-nested case-control analysis (20); the ARIC study demonstrated higher folate and B₆ intake to be associated with lower CVD risk but associations with higher homocysteine were not significant (21); and the Nurses’ Health Study investigators found that higher folate and B₆ intake was associated with lower cardiovascular risk. Elevated homocysteine concentrations in the plasma may potentiate thrombin generation and may have relevance in the setting of acute coronary syndromes. A study of approximately 100 persons with acute coronary syndromes was found to have positive associa­tions with F1 + 2 and Factor Vila levels. It has been proposed that hyperho- mocysteinemia potentiates a procoagulant state that may adversely affect the en­dothelium and enhance tissue factor activity.

Large-scale interventional data that reduce homocysteine levels and dem­onstrate favorable effects on cardiovascular risk are lacking, but vitamin supple­ments are being included in a variety of ongoing studies and the results should be forthcoming. The minimal daily dose of folic acid that appears to have maximal efficacy to decrease plasma homocysteine is estimated as 0.4 ^g/day, with higher doses not generally being more effective. It is recommended that vitamin B₁₂ deficiency be ruled out prior to initiating folic acid therapy. Alterna­tively, persons on folic acid therapy can be supplemented with a dose of 400 to 1000 |J.g/day of vitamin B₁₂. The dose of vitamin B₆ recommended was 25 to 50 mg/day and there is little risk of developing complications such as sensory neuropathy at this supplement level.

Loryna Lawyer News: Additional Info and News

Loryna Lawyer: New factors associated with increased risk for coronary heart disease arouse great interest and enthusiasm, kindling the hope that we may enhance identification of individuals at risk for CHD. Important concerns are that such metabolic factors be biologically plausible, measurable, repeatable, strong, graded, and treatable (37-39). Measurement issues include accuracy and precision for the factor in the laboratory and evidence of low or modest variability in the clinical setting. If the laboratory or biological variability is very large, the utility of the measurement for predictive purposes is seriously reduced. Many years of experience and stan­dardization of measurements are available for some vascular risk factors, and less experience is available for homocysteine. New risk factors may provide clues to pathogenesis and in some instances may improve our ability to predict disease. The ability to predict new vascular disease events should be demonstrated after consideration of the core set of factors that are currently available, including age, sex, blood pressure, cholesterol or LDL cholesterol, HDL cholesterol, smoking, and diabetes mellitus. This criterion is often not met in new investigations and considerable experience and relatively large data sets and follow-up may be nec­essary to assure that new factors, such as homocysteine, prove useful in predicting vascular disease risk.

Elevated homocysteine levels may be accompanied by decreased blood levels and intake of folate, vitamin B₆, or vitamin B₁₂. These vitamins are important cofactors in the metabolism of homocysteine, and border­line deficiencies are relatively common, affecting approximately 30% of the el­derly participants in the Framingham Heart Study. Greater intake of these vitamins in the diet, with supplements in the form of multivitamins, or through fortification of foods, has led to less vitamin deficiency and a decrease in the prevalence of elevated homocysteine levels. Fortification of the food supply in the United States with folate was announced in early 1996 with a mandated enactment date of January 1, 1998. Analyses of homocysteine and folate levels before and after fortification have been undertaken in Framingham Heart Study participants and showed a dramatic decline in the prevalence of low folate levels, a reduction in the prevalence of elevated homocysteine from approximately 20 to 10%, and a modest decrease in mean homocysteine levels from approximately 10 to 9 |J.mol/L.

Lupus anticoagulants or nonspecific inhibitors interfere with the assembly of procoagulant complexes. In vitro, these antibodies are associated with the pro­longation of phospholipid-dependent blood-clotting times. Characteristically, clotting times return to normal with the addition of exogenous phospholipid. Lu­pus anticoagulants may demonstrate specificity for blood-clotting proteins, in particular prothrombin. However, the mechanism by which they promote throm­bosis is unknown. Lupus anticoagulants are likely associated with a high risk of first and recurrent thrombosis as well as recurrent pregnancy loss.

LAC are a heterogeneous group of autoantibodies, which prolong the clot­ting time in a variety of assays and may demonstrate specificity for beta- 2 glycoprotein-1. LAC do not prolong clotting times in assays in which phospholipid is present in excess. This suggests that LAC inhibit in vitro coagula­tion by interfering with the assembly of procoagulant complexes on phospholipid surfaces. This observation also forms the basis for the test for LAC—a prolonged clotting time, in a phospholipid-limited assay system, that normalizes with the addition of excess phospholipid confirms the presence of LAC. Anecdotal experi­ence suggests that lupus anticoagulants are much less common than anticardio- lipin antibodies, that they are infrequently transient, and that they are associated with a high risk of complications, although none of these observations has been adequately studied. Furthermore, laboratory assays for lupus anticoagulants.­

Our use of the term or terms Loryna Lawyer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Loryna Lawyer visit our site often.

Loryna Lawyer

Loryna Litigation News – 2/16/2012: If you were prescribed Loryna and have suffered negative side effects, please contact us today so that we can put you in touch with an attorney to advise you of your legal rights.

Loryna Litigation: Two recent large trials have studied the efficacy and safety of aspirin in patients with acute ischemic strokes. The International Stroke Trial ran­domized 19,435 patients with acute ischemic stroke to unfractionated heparin, either 5,000 or 12,500 units twice daily, aspirin 300 mg daily, or both heparin and aspirin (11). Among the patients treated with aspirin, there were 2.8% recurrent ischemic strokes within 14 days, compared to 3.9% in the groups not receiving aspirin, and no excess of hemorrhagic strokes. There was a nonsignificant trend for decreased mortality in patients treated with aspirin compared to those not treated with aspirin at 14 days (9% vs. 9.4%). At 14 days, therefore, there was a significant reduction in death or any nonfatal recurrent stroke in the aspirin- treated group (11.3% vs. 12.4%). In patients treated with heparin, there were 2.9% recurrent ischemic strokes within 14 days compared to 3.8% in the groups not receiving heparin, but an increase in hemorrhagic strokes (1.2% vs. 0.4%). As a consequence, there was no significant difference in the incidence of nonfatal recurrent stroke or death between the heparin and nonheparin groups (11.7% vs. 12%, respectively).

Several trials have studied the efficacy of aspirin as primary prevention for myo­cardial infarction, stroke, and death, but the results have not been consistent. The Physicians’ Health Study compared aspirin to placebo in 22,071 male physicians over the age of 40 and followed them for 5 years. Myocardial infarction occurred in 139 persons assigned to aspirin and 239 assigned to placebo. Thus, aspirin was associated with a 44% reduction in the risk of myocardial infarction. Cardiovascular death occurred in 81 persons assigned to aspirin and 83 assigned to placebo. Thus, there was no significant reduction in total cardiovascular mor­tality. The reduction in the risk of myocardial infarction occurred only among men 50 years of age and older. There was a nonsignificant, slightly increased risk of stroke among those taking aspirin compared to those taking placebo. A separate study of 5139 healthy British male physicians compared aspirin to pla­cebo. Total mortality was slightly, but not significantly, less in the control group compared to the aspirin-treated group. There was no significant difference in the incidence of nonfatal myocardial infarction or stroke.

Another British trial, the Thrombosis Prevention Trial, evaluated the effect of low-dose aspirin (75 mg/day) as well as oral anticoagulation with warfarin (average INR = 1.47) in 5499 healthy men aged 45 to 69 years who were random­ized to warfarin, aspirin, both, or neither. The average International Normal­ized Ratio (INR) for those receiving warfarin was 1.47. Warfarin was associated with a 21% reduction in coronary death, fatal, and nonfatal myocardial infarction, and aspirin was associated with a 20% reduction in coronary death and myocar­dial infarction. The risk of hemorrhagic and fatal strokes was increased in the warfarin-treated patients. The principal effect of aspirin was primarily a 32% reduction in nonfatal myocardial infarction; aspirin did not reduce total cardiovas­cular mortality. The effect of aspirin as primary prevention was also evaluated in 87,678 U.S. registered nurses who had been participating in a prospective cohort study. Among women taking one to six aspirin per week, there was a significant, 32% relative risk reduction for myocardial infarction, a nonsignifi­cant, 11% relative risk reduction for cardiovascular death, and no decrease in the risk of stroke.

An analysis of 21 trials included in the Antiplatelet Trialists’ Collaboration found that the odds ratio among persons using aspirin for upper gastrointestinal bleeding was 1.7; for peptic ulcer, 1.3; and for all gastrointestinal bleeding, 1.5 to 2.0. The risk of cerebral hemorrhage is increased by aspirin. A recent metanal- ysis of 16 trials constituting 55,462 persons found that the absolute risk of hemor­rhagic stroke in groups treated with aspirin was 1.2 per thousand individuals accounting for a relative risk of 1.84. Hypersensitivity reactions to aspirin, including nasal congestion, urticaria, and bronchospasm may occur. The frequency of these adverse effects in patients with chronic urticaria is 23%, in patients with asthma is 4 to 19%, and in patients with nasal polyps is approxi­mately 23%.

Loryna Litigation News: Additional Information and Resources

Loryna Litigation: The Studio della Ticlopidinia nell’Angina Instabile Groupe evaluated the efficacy of ticlopidine in 652 patients with unstable angina. Following treat­ment for 6 months, 7.3% of the patients receiving ticlopidine had a nonfatal myocardial infarction or vascular death compared to 13.6% of patients who did not receive ticlopidine, accounting for a 46.3% relative risk reduction. Several trials have evaluated the efficacy of ticlopidine in preventing throm­bosis or ischemic events subsequent to placement of an intracoronary stent. The Full Anticoagulation versus Aspirin and Ticlopidine (FANTASTIC) study ran­domized patients to aspirin and ticlopidine or to aspirin and conventional antico­agulation with heparin or oral anticoagulants. The primary endpoint of bleed­ing or peripheral vascular complications occurred in 13.5% of patients treated with aspirin and ticlopidine and 21% of patients treated with aspirin and anticoag­ulants. The overall incidence of stent occlusion was similar in each group; yet, acute stent occlusion occurred more frequently in the antiplatelet group (2.4 vs. 0.4%), whereas subacute stent occlusion within 1 week occurred more frequently in the anticoagulant group (3.5 vs. 0.4%).

The Multicenter Aspirin and Ticlopidine Trial after Intracoronary Stenting (MATTIS) study randomized 350 high-risk patients following stent implantation to aspirin and ticlopidine or to aspirin and oral anticoagulation. After 30 days, the primary cardiac endpoint of cardiovascular death, myocardial infarction, or repeated revascularization occurred in 5.6% of the aspirin and ticlopidine group compared to 11% of the aspirin and anticoagulant group, accounting for approximately 50% reduction in the risk of an adverse event with the former compared to the latter group. Schomig et al. randomized 257 patients undergoing placement of coronary artery stents to aspirin and ticlopidine, or to aspirin plus anticoagulation with heparin or phenprocoumon. The primary cardiac endpoint of cardiac death, nonfatal myocardial infarction, coronary artery bypass surgery, or repeat angio­plasty occurred in 1.6% of patients randomized to aspirin plus ticlopidine as compared to 6.2% of those randomized to aspirin plus anticoagulation, account­ing for a relative risk of 0.25 in those randomized to antiplatelet therapy alone. Moreover, hemorrhagic complications occurred in 6.5% of the anticoagulant ther­apy group, but in none of the antiplatelet therapy group.

Two large clinical trials evaluated the efficacy of ticlopidine in patients with symptomatic cerebrovascular disease. The Canadian American Ticlopidine Stud­ies (CATS) randomized 1072 with recent thromboembolic stroke to ticlopidine or placebo and followed them for an average of 24 months. The primary endpoint of stroke, myocardial infarction, or vascular death occurred in 15.3% per year of those treated with placebo and 10.8% per year of those treated with ticlopidine, accounting for a relative risk reduction with ticlopidine of 30.2%. There was no significant difference in the total mortality rate, which was 4.5% per year in those receiving placebo and 4.1% per year in those receiving ticlopidine. The Ticlopidine Aspirin Stroke Study (TASS) randomized 3069 patients with recent transient ischemic attack, amaurosis fugax, or minor stroke to aspirin or ticlopidine.

Several studies have examined the efficacy of ticlopidine in patients with periph­eral arterial disease. Balsano etal. studied 151 patients with intermittent claudica­tion who were randomized to treatment with ticlopidine or placebo. Improve­ment in pain-free and maximal walking distance was greater in the ticlopidine than in the placebo group. The Swedish Ticlopidine Multicenter Study (STIMS) assessed the effect of ticlopidine on cardiovascular events in 687 patients with intermittent claudication followed for a median duration of 5.6 years. The incidence of myocardial infarction, stroke, and transient ischemic attack was 29% in patients treated with placebo compared to 25% among those treated with ticlopidine, accounting for a risk reduction of 11.4% in favor of ticlopidine. Mortality was 26.1% in the placebo group and 18.5% in the ticlopi­dine group, accounting for a relative risk reduction of 29%. A recent metanalysis involving studies of patients with intermittent claudication found that mortality was significantly decreased by ticlopidine compared to placebo, with an odds ratio of 0.68.

Loryna Litigation News: News and Information from related Sources

Loryna Litigation: Several additional trials that are assessing the efficacy of clopidogrel in preventing cardiovascular events are currently taking place. These include: the Clopidogrel Reduction of Events During Extending Observation (CREDO) trial in which patients undergoing percutaneous revascularization will receive clopido­grel with aspirin for 1 year versus clopidogrel plus aspirin for 1 month followed by aspirin for another 11 months and the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial in which patients with congestive heart failure will be randomized to warfarin (titrated to an INR of 2.5-3.0), clopidogrel 75 mg/day, or aspirin 160 mg/day, and followed for up to 5 years.

In the CAPRIE trial, bleeding occurred with comparable frequency in the patients receiving clopidogrel compared to aspirin (9.27% vs. 9.28%, respectively). In patients receiving clopidogrel, intracranial hemorrhage occurred in 0.35% and gastrointestinal hemorrhage in 1.99%, the latter being less frequent than in pa­tients receiving aspirin. In patients receiving clopidogrel, diarrhea occurred in 4.46% and rash occurred in 6.02%. Of patients receiving clopidogrel, neutro­penia (<1200/|J.L) was present in 0.1%, severe neutropenia (<450/|J.L) in 0.05%, thrombocytopenia (<100 X 10³/|J.L) in 0.26%, and severe thrombocytopenia (<80 X 10³/|J.L) in 0.19% of patients receiving clopidogrel. A recent report high­lighted the potential association of thrombotic thrombocytopenic purpura with clopidogrel (41). Eleven patients who had been treated with clopidogrel, 10 of whom had been treated for 14 days or less, were identified over a 2-year period by active surveillance of medical directors of blood banks, hematologists, and a surveillance overseen by pharmaceutical manufacturers. At the time of this report, the authors estimated that more than 3 million people had received clopidogrel. Idiopathic thrombotic thrombocytopenic purpura has been estimated to occur in approximately 3.7 per million.

Heart failure was the first major area in which ACE inhibitors have proven their undisputed role in improving clinical outcomes, indeed, survival. In the early 1980s, the ‘‘vasodilator era,’’ then pioneering acute studies revealed that favor­able hemodynamic improvements could be obtained by ACE inhibitors in patients with severe heart failure. The first demonstration of a survival benefit with the use of an ACE inhibitor in any cohort of patients can be attributed to the Cooperative North Scandinavian ENalapril SUrvival Study (CONSENSUS), which randomized patients with severe heart failure. In this trial, despite the use of digitalis, diuretics, and other vasodilators, the placebo mortality rate was exceedingly high, approaching 50% at 6 months. Those randomized to the active therapy (enalapril) had a pronounced reduction in the risk of death. Indeed, the combination of the high placebo event rate and the relative effectiveness of ther­apy led to conclusive results in a population of approximately 500 patients.

The Studies of Left Ventricular Dysfunction (SOLVD) greatly expanded the indications for ACE inhibitors as a consequence of their results in two parallel randomized trials collectively involving over 6000 patients. In the treatment arm, symptomatic heart failure patients with left ventricular dysfunction (ejection fraction <35%) of all etiologies were randomized to placebo or enalapril. Despite background therapy with digitalis or diuretics or both, the enalapril group experi­enced a 16% reduction in the risk of death and clear reductions in the need for rehospitalization for heart failure. The same screening procedures identified and randomized over 4000 patients who also had left ventricular dysfunction. However, the study investigators did not feel that these patients had sufficient symptoms to warrant therapy—the Prevention Arm. In this unique group, the randomization to enalapril showed a favorable trend for a reduction in fatal events with a clear reduction in the development of heart failure during the ap­proximately 4 years of follow-up. As a consequence of these and other smaller studies, ACE inhibitors had proven themselves as an essential, indeed, ‘‘corner­stone’’ therapy for the management of patients with heart failure. In some respects, the V-HeFT-II study put the icing on the cake for the use of ACE inhibi­tors in heart failure. It showed that, in a group of symptomatic heart failure pa­tients randomized to either the combination of hydralazine and nitrates (the first life-sustaining therapy for heart failure) versus enalapril, the ACE inhibitor re­sulted in superior survival even compared to a previously proven therapy for heart failure. Taken together, we now had clear evidence that the morbidity and mortality of heart failure could be effectively reduced by the use of an ACE inhibitor.

Loryna Litigation News: Information and News

Loryna Litigation: The rationale for the treatment of patients with myocardial infarction with an ACE inhibitor stems from the pioneering work of the late Dr. Janice Pfeffer, beginning when she was a fellow in the Braunwald laboratory. Experimental models of infarctions were readily utilized to determine whether infarct size could be favorably modified by pharmacological therapy. Pfeffer explored the relation­ship between infarct size and ventricular function and incorporated important lessons from her doctoral training in hypertension at Edward Frohlich’s labora­tory to determine the long-term consequences of abrupt loss of myocardium from coronary ligation. Indeed, she demonstrated in the animal model that the loss of myocytes should be viewed as the beginning of an insidious phase of progressive ventricular enlargement (remodeling), which is related both to the extent of the histological damage as well as to the duration of time from the infarct. In­deed, the enlargement itself is a central component in the progressive worsening of dysfunction. Ventricular remodeling could also involve the normal remaining myocardium, which, as a consequence of unfavorable geometry and wall stress, could suffer an abnormal hemodynamic burden.

These observations of ventricular remodeling provided a new therapeutic target for a novel use of ACE inhibition—to attenuate time-dependent ventricular enlargement following infarction. The use of ACE inhibitors was a natural exten­sion of her work in hypertension, where these agents were particularly effective in preventing hypertrophy and left ventricular chamber enlargement. In the myocardial infarction model, long-term administration of an ACE inhibitor did indeed attenuate ventricular enlargement as treated animals had smaller left ven­tricular cavities and more preserved ventricular pump function. In a subse­quent study, a prolongation of survival was demonstrated with ACE inhibitor treatment.

These animal studies provided the rationale for initially small mechanistic studies, which confirmed both the process of progressive enlargement post-myo­cardial infarction and the attenuation of enlargement with the use of an ACE inhibitor. These mechanistic studies were soon followed by an extensive series of international multicenter randomized trials testing the hypothesis that administration of an ACE inhibitor to patients in the acute and chronic phases of myocardial infarction would lead to improved survival. The Survival and Ven­tricular Enlargement (SAVE) study, as suggested by the trial’s acronym, tested the hypothesis that attenuation of ventricular enlargement in high-risk patients post-myocardial infarction would lead to improved survival. The SAVE study demonstrated that the addition of captopril to a conventionally treated pa­tient who survived a myocardial infarction with an ejection fraction less than 40% without overt heart failure would lead not only to a reduction in the risk of death, but also to a reduced risk of developing heart failure and experiencing a recurrent myocardial infarction. A detailed quantitative echocardiographic study did confirm an attenuation in remodeling in the ACE inhibitor group and, more­over, these investigators were able to demonstrate linkage between progressive enlargement, risk of an adverse cardiovascular event, and the favorable benefit of the ACE inhibitor therapy.

The Acute Infarction Ramipril Efficacy (AIRE) study administered the ACE inhibitor ramipril to patients starting in the acute phase of the infarct and continuing long term. The AIRE investigators identified high-risk patients based on clinical signs or symptoms of pulmonary congestion or transient heart failure. The long-term administration of the ACE inhibitor resulted in a 26% reduction in the risk of death and comparable reductions in other nonfatal cardiovascular endpoints. The TRandolapril Cardiac Evaluation (TRACE) investigators employed echocardiographic assessment of wall motion to identify higher risk acute infarct patients. Here, again, the randomization to the ACE inhibitor resulted in an im­portant reduction in the risk of death. In the Survival of Myocardial In­farction Long-term Evaluation (SMILE), the ACE inhibitor zofenopril was ad­ministered to patients with anterior myocardial infarction who had not received thrombolytic therapy. This randomized trial demonstrated a reduction in risk of death or development of heart failure during only 6 weeks of therapy. The TRACE and AIRE investigators have extended their observations beyond the formal trial period and demonstrated that the survival benefits persisted.

Our use of the term or terms Loryna Litigation is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Loryna Litigation News visit our site often.

Loryna Litigation

Loryna Side Effect News- 2/16/2012: You deserve to be compensated if you took Loryna and suffered side effects that the public was not warned about. Contact us today and we will arrange a free consultation with a lawyer experienced in pharmaceutical and medical device ligation that can advise you of your legal rights.

Loryna Side Effect: Until recently, we only had aspirin, but now a number of new, highly effective medications have been approved to decrease platelet stickiness and prevent the formation of blood clots. The last few years have brought remarkable progress and hope for the stroke survivor. In addition to our good old standby aspirin, the “Grande Dame” of blood clot prevention, we now have multiple medications that also decrease platelet stickiness and clot formation—and go a long way toward preventing anoth­er stroke or vascular death. One has only to turn on the television or open a magazine and you will see advertisements for these medications.

Furthermore, treating a stroke patient’s depression with an­tidepressants also has been found to enhance his physical and cognitive rehabilitation. Each antidepressant has its own side effects, including sleep disturbances, agitation, and sexual dysfunction. Some of the old­er antidepressants interfere with cognition (the ability to “know”) and should be avoided. A clinician must take a patient’s individu­al stroke symptoms into account when determining which medi­cation is best. Our newer antidepressant medications are so effective that frequently the importance of psychology is ignored. However, both medication and counseling are important. Studies have shown that used together the result is superior to either used alone.

When physicians mention the use of a stimulant medication, the first reaction is usually less than enthusiastic. Patients and their families picture children with attention deficit disorders or con­jure up the horrors of amphetamine abuse. But this close-minded thinking may make them miss a very important treatment both in the early and latter phases of stroke rehabilitation. According to experimental evidence, ani­mals treated with amphetamines immediately after their stroke recover to a higher functional level. In other words, stimulants may either have a protective effect on brain cells or assist in their recovery after a stroke. This is still far from common practice in most acute care hospitals, but that can change as more research shows the effectiveness of these medications.

Loryna Side Effect News: More information about your search

Loryna Side Effect: Like their antidepressant cousins, tranquilizers can help decrease the emotional anxiety that accompanies stroke, which, if left un­checked, could sabotage the rehabilitation process. And this anxiety is very real. The fear of a stroke recurring, the fear that it is still in progress, the overwhelming fear of how their lives will change—all these can create irritability, anxiety, and insomnia. Tranquilizers can help ease the pain of these fears, but, as with antidepressants, they must be closely monitored. They can interfere with cognitive abilities. Their use should be “time lim­ited” to avoid dependence. Side effects include drowsiness, dizziness, and possible addiction.

Yes, stroke survivors can have seizures, but they are not common. If someone you love suffers from seizures as a result of stroke, however, there is help. Anticonvulsants usually will control sei­zures. However, regular blood tests will be required to adjust the dosage. The proper levels must be present in blood in order for this medication to work. Too little and it will not be effec­tive against seizures; too much and there is the danger of side effects—which include nausea, drowsiness, balance problems, and liver abnormalities.

Although not a medication, it seemed best to cover this procedure in this chapter. Carotid endarterectomy is an operation that is performed when too much cholesterol has built up in the carotid artery in the neck. Developing the skills to perform this operation has not been as difficult as deciding which patient is an appropriate candidate. Recently, a large study helped identify which patients would ben­efit most; the findings show that determination should be based on how much the carotid artery is narrowed and whether the per­son is currently experiencing any stroke symptoms.

When injured or in pain, we want to go to the best doctor, the best specialist, for our condition. When it comes to dental work or orthodontics, we want to know we are in good hands. Even outside the world of medicine, the best is something we strive for: a restaurant to celebrate a birthday, a vacation in the sun, a car for our family. We want to try, as much as possible, to get the best quality for our money.

Rehabilitation is no exception. There are good rehabilita­tion facilities and there are bad ones—and which you choose can make all the difference in whether or not your loved one gets the care he needs and deserves. And, believe it or not, there are re­habilitation facilities that are better than others—at the same or lower cost. Further, since studies have shown that the average stroke survivor lives an additional seven and a half years, there is no doubt that doing some “rehabilitation detective work” and finding the right facility can have positive results!

Loryna Side Effect News: Additional Information and Resources

Loryna Side Effect: True, there are certain rules, specific guidelines, that thera­pists must follow. Therapists must be trained and educated very carefully. They are required to receive an advanced degree in their specific area, in addition to hands-on work in the field. In short, by the time you see any of the therapists on your rehabilitation team, they have had a great deal of education and experience. But there is more than expertise at work in rehabilitation. Some people have that extra “something,” a talent that school- books cannot supply. A therapist who interacts with you in a way that makes you feel secure, who motivates your loved one to try her very best, who helps and doesn’t hinder—this is a rehabilita­tion therapist worth seeking out. A good facility will have this type of therapist on staff. It should be the unspoken credo of the entire rehabilitation team.

Although the ads you see for nursing homes make them sound like a dream come true for the elderly—more like resorts or rehabilitation facilities than nursing homes—the reality is that they do not always ensure progress, and they may even hinder ul­timate success. Changing a sign on the building from ABC Home for the Aged to ABC Rehabilitation Center doesn’t change the facts. The statistics speak for themselves: studies have found that patients in inpatient rehabilitation hospitals were three times more likely to be discharged home than those who went to nursing homes.

Do stroke patients do as well in a skilled nursing facility as in a true rehabilitation hospital? Are they as likely to be discharged home and back to the care of their loved ones? The answer to both questions: definitely not! And there are scientific studies to prove it. That’s right: three times more likely to sleep in their own bed, eat with their families, and kiss their grandchildren goodnight. Knowing this, where would you or a loved one want to go if you had a stroke?

The goal of a human being is to be independent and to en­joy a life that is as productive and of good quality as possible. A person who has had a serious illness or injury is no excep­tion. Whether it’s as basic as helping a person who has had a stroke learn bladder and bowel routines so that she can maintain some level of independence and dignity, or as complex as aid­ing a person who has lost her memory, rehabilitation works for your loved one, your family, and you. The highest correlation of self-esteem in a person is the ability to control one’s bladder and bowels. Inpatient rehabilitation facilities have entire programs to focus just on this area.

Loryna Side Effect News: News and Information from related Sources

Loryna Side Effect News: Hospital acute care. This is the place you go to immedi­ately after an accident or a stroke. It is the “emergency room of rehabilitation care” where you’ll find an actual emergency room, an intensive care unit, and operating rooms. In an ideal world, rehabilitation starts here. A medical team performs a variety of diagnostic tests that may include a blood workup, x-rays, or brain scans. A respiratory therapist will ensure that lungs are kept clear. Other members of the rehabilitation team will provide proper po­sitioning and movement to prevent bedsores, weakened muscles, or spasticity.

Day program. Think of a day program as the workplace or a school. In this type of rehabilitation program, you will receive all of the usual therapies and medical treatments with a daily “work” day that may last from four to eight hours. At day’s end, the patients return home to sleep, eat, and be with their families. This is the perfect setting for the patient who still needs multiple therapies but is able to return home at night and on the weekends to be with her family. Transitional living. This is exactly as it sounds: a transi­tional residence that is halfway between a rehabilitation hospital and home, sweet home. It is a place for those who have “gradu­ated” from their rehab program, but are not yet ready to reen­ter their community and live at home. In this supervised setting, people work on such skills as menu preparation, group social skills, and behavior management, while continuing their reha­bilitation program.

Rehabilitation does not take place in a vacuum. Work performed on the lower extremities is not done without coordination of speech and other therapies. It is not a question of three weeks for physical therapy, followed by six weeks for speech, and ending with four weeks for relearning such basic skills as using a knife and fork and getting dressed.

The rehabilitation team works together, implementing and reinforcing this interrelated approach. The speech therapist knows the progress a patient is making in language and cogni­tive therapy. The occupational therapist knows where the patient stands in activities of daily living. Each team member works in concert with the others, in communication with the others, even working side by side with the others. This makes sense: as a pa­tient learns to use a wheelchair, he also might be learning how to make change in a supermarket. As he learns to walk from his bed to the bath, he also is learning how to shower and get dressed.

Our use of the term or terms Loryna Side Effect is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Loryna Side Effect News visit our site often.

Loryna Side Effects

Tysabri Brain Infection Lawsuit News – 2/22/2012: Please contact us today if you took Tysabri and suffered unusual side effects or other injuries.

Tysabri Brain Infection Lawsuit: The brain directs every voluntary activity in the body (motor functions and the musculoskeletal system), stimulates respiration, oversees digestion, manages growth and development, ensures tissue repair, and serves as Grand Central Station for the nervous system. (The brain contains 6 mil­lion nerve cells, fully half of the body’s entire supply.) The brain is our in­terpreter of the outside world, monitoring information supplied by our five senses. It is also, of course, the center of our thoughts, feelings, and emo­tions. In fact, it is specially constructed for processing that complex mix.

The human brain is divided into two sections—a newer, outer layer called the neocortex or the cerebral cortex, and a more primitive interior re­gion known as the Old Brain or archipallium. The neocortex, called “neo” because it is believed to have evolved more recently, is the seat of percep­tion, learning, cognition, conscience, and morality. The Old Brain, includ­ing the hippocampus and brain stem, is where our moods and emotions dominate—fear, anxiety, happiness, love, excitement, and so on. All mam­mals have the equivalent of our Old Brain, but the large, overdeveloped, multi-wrinkled outside (the neocortex) sets humans apart.

Specialized nerve cells called neurons are the fundamental structure of the brain. The human brain has 100 billion neurons, and each one has as many as 100,000 links to other neurons. It transmits billions of messages between neurons every second. To get over the gap, or synapse, between neurons, those messages rely on chemicals known as neurotransmitters. Neurons store neurotransmitters, releasing them in response to electri­cal signals. The neurotransmitter then attaches to receptors on nearby neu­rons, triggering another electrical signal. This is the way moods, thoughts, emotions, and impulses move throughout the brain. Receptors on neurons are specific to certain neurotransmitters—like a lock and key.

Tysabri Brain Infection Lawsuit News: More information about your search

Tysabri Brain Infection Lawsuit: You never get any more neurons than you are born with. In fact, the brain loses nerve cells as it ages (and in the event of brain injury). Aging also cuts down on the number of extensions from the neu­rons (dendrites) that connect to other neurons, so communication between brain cells gets more difficult the older you get. Levels of some of the neurotransmitters charged with carrying positive feel­ings decrease. In addition, by age forty-five, levels of a powerful enzyme that is responsible for breaking down several types of neurotransmitters increase. The stepped-up breakdown can throw your brain chemistry out of balance and lead to, among many other things, a decrease in the general level of brain activity, inter­ference with the ability to think and remember, and depression.

Certainly, none of this has to mean senility or the loss of mental function that we (wrongly) associate with getting older. You have plenty of neurons to keep you mentally strong for your entire life if you care for them well; and providing the materials for all the neu­rotransmitters you need is within your control. But aging can mean that your brain chemistry tips out of balance more easily if you don’t provide proper nutrition. Looking at it another way, people may get away with sloppy eating habits in their youth, but those habits eventually catch up with them.

The disproportionate opportunities for failure, rather than success, make it that much more crucial that our brains get a constant supply of the correct neurotransmitters, and the raw materials for making them, in order to keep working smoothly. By and large, neurotransmitters become inactive once they’re delivered a message, and they need to be replenished. Though they exist throughout the body, they cannot move into the brain from out­side it, in order to protect it from fluctuations of neurotransmitters in the blood. Instead, they are made “on site”—in the brain, where and when they are needed. (It is also possible to have too much of a particular neurotrans­mitter, and breakdown is an important step in controlling this. Your body will make only what it needs from available materials.)

Tysabri Brain Infection Lawsuit News: Additional Information and Resources

Tysabri Brain Infection Lawsuit: Neurotransmitters are made from amino acids (the building blocks of all proteins), which we get from the food we eat. Poor diet, then, can leave us without the ability to make the chemical messengers necessary for healthy brain function. Optimal nutrition, through high-quality food and, as necessary, supplements, maintains balance in the brain, which allows for a plentiful supply of the appropriate neurotransmitters and a general mood of well-being and comfort. Your brain physically changes in response to your experiences. Neu­rons develop new connections thanks to new sensations and even thoughts. While you learn something, or try something new, or go through something for the first time, your brain actually grows or alters its structure to accommodate that information.

An electron microscope is an imposing instrument, about six feet high, housed inside a small darkened room designed exclusively for this instrument and the support equipment it requires—high voltage trans­formers, vacuum pumps, and a liquid nitrogen tank. A heavy steel col­umn about ten inches in diameter rises up to the ceiling from a workstation console, encrusted with buttons, switches, knobs, flashing indicator lights, digital numerical displays, and video monitors. Sprout­ing out of the top of the column is a heavy, two-inch-diameter electrical cable, which delivers 100,000 volts to the electron gun at the top of the column. Liquid nitrogen billows out a white cold fog spilling down from the top of the column in the darkened room like liquid oxygen from a rocket on the launchpad at dawn.

After placing the sample in the microscope and energizing the electron gun, Morest sees shadowy patterns come into focus on a phos­phorescent screen. Anyone not trained in interpreting these shadowy patterns would see nothing more than grey doodles on a glowing yel- low-green background. But the electron microscopist, with his head pressed against the column to look at the glowing screen through a thick glass window, is transported inside a cell of this rat’s brain. The tiny slice is now expanded into an immense new universe. Turning wheels simul­taneously with both hands he moves the grid, scanning acres of cellular territory for hours, completely absorbed in the new world he is seeing. Hours later he emerges from the room with a telltale flat spot embossed into the center of his forehead from pressing it against the column.

Increasing the magni­fication in an electron microscope is like seeing the ground spinning below as you descend swinging from a parachute, bringing greater and greater detail as you approach the ground. Mo rest must keep his bear­ings through all of these dizzying twists, maintaining a conceptual thread back through the slicing process to the way the tissue was ori­ented in the brain of the rat He will have to analyze hundreds of sections to reconstruct the three-dimensional cellular structure correctly, a pro­cess requiring months or years of work.

Tysabri Brain Infection Lawsuit News: News and Information from related Sources

Tysabri Brain Infection Lawsuit:

Some research­ers suggest that augmenting these beneficial actions of microglia would be the best therapy Microglia do indeed target and kill neurons that are infected with the disease-causing prions and thus they do damage neu­ral circuitry, but in doing so they may protect the brain by limiting the spread of the diseased prion. Microglia also engulf the deposits of PrP outside neurons, thus eliminating or slowing the accumulation of PrP plaques. Once infected by prion, however, the ability of microglia to consume particles of PrP becomes impaired. Dysfunctional microglia might even contribute to the disease, making some people more suscep­tible to prion infection than others.

This is essential for synaptic transmission and to prevent glu­tamate from rising to toxic levels. In CJD, microglia transform to take over this vital function as astrocytes become infected and die. The trans­porter molecule in the cell membrane that absorbs the n euro transmitter glutamate into astrocytes starts to be synthesized in microglia during prion infection. Now equipped with the glutamate transporter of astro­cytes, microglia step in for their fallen glial comrades to lower the toxic levels of this neurotransmitter in damaged brain tissue. This protects neurons from death due to overstimulation by the excess glutamate.

Finally, microglia could be helpful in diagnosing prion disease. Microglia develop distinct cellular changes in response to prion infec­tion, and these alterations can be detected with appropriate diagnostic techniques. Much as monitoring changes in blood cell count informs doctors of the type and severity of infections in the body, one can imag­ine that careful monitoring of changes in microglia could provide criti­cal insight into infection in the brain. Interestingly, current evidence suggests that oligodendrocytes are not capable of supporting replication of the infectious prion protein. Tin’s resistance sets them apart from both neurons and astrocytes. However, oligodendrocytes and myelin suffer damage in prion disease. Other studies indicate that oligodendrocytes are killed by oxidative injury ac­companying prion infection.

Our use of the term or terms Tysabri Brain Infection Lawsuit is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Tysabri Brain Infection Lawsuit News visit our site often.

Tysabri Brain Infection

Tysabri Class Action Lawsuit News – 2/22/2012:You deserve to be compensated if you took Tysabri and suffered side effects that the public was not warned about. Contact us today and we will arrange a free consultation with a lawyer experienced in pharmaceutical and medical device ligation that can advise you of your legal rights.

Tysabri Class Action Lawsuit: Recall that PrP is a normal protein in neurons that becomes mutated and infectious in prion disease. The biological role of the normal PrP in cells is still mysterious. In 2005 it was reported that normal PrP is found in purified myelin and in oligodendrocytes. In 2007, Frank Baumann and colleagues from the University Hospital of Zurich, Switzerland, re­ported that a mutation in a particular part of PrP caused myelin break­down in both the central and peripheral nervous systems of mice. This study suggests that myelin integrity must be maintained by some un­known action of the normal PrP in myelin. By studying the role of PrP in myelin, we may learn more about the normal function of this protein in cells.

How do the 100 billion neurons in our brain allow us to remember who we are; to learn, think, and dream; to be stirred by passion or rage; to ride a bike or conjure meaning from inked patterns on paper; or to pluck out instantly a mothers voice from the muddle of a noisy crowd? What goes wrong with neural circuits in schizophrenia or depression, or in dreadful diseases like Alzheimer’s, multiple sclerosis, chronic pain, or paralysis?

We are on the cusp of a new understanding of the brain that trans­forms a century of conventional thinking about the brain, specifically the role of the brains neurons. Crowding around the computer screen in a darkened room in 1990, scientists watched information passing through peculiar brain cells, bypassing neurons and communicating without using electrical impulses. Until this discovery scientists had presumed that information in the brain flowed only through neurons by using electricity. In fact, a mere 15 percent of the cells in our brain are neurons. The rest of our brain cells—called glia—have been over­looked as little more than packing material stuffed between the electric neurons. “Housekeeping cells” they were called. Dismissed as cellular domestic servants, glia were neglected for more than a century after they were discovered.

A neuron from the brain of a genius was indistinguishable from one taken from a typical brain. And on average, there were just as many neurons in Einstein’s creative cerebral cortex as in the cortex of men not noted for being unusually creative. But there was one difference in the data. The number of cells that were not neurons was off the charts in all four areas of Einsteins brain. On average, the samples from normal brain tissue had one cell that was not a neuron for every two neurons counted, but the samples from Einsteins brain had nearly twice as many nonneuronal cells, about one for every neuron. The biggest difference was seen in the sample of parietal cortex from the dominant side of Einsteins brain, the region where abstract concepts, visual imagery, and complex thinking take place. Was this a fluke? Diamond calculated the mathematical odds that this difference could have happened by chance, considering the range of variation in the control tissue samples. In all the regions sampled from Einsteins brain the odds that the difference could have occurred by chance were small.

Tysabri Class Action Lawsuit News: Information and News

Tysabri Class Action Lawsuit: The rest of the brain is white matter. This glistening-white brain tissue is a mass of millions of tightly bundled communication lines connecting neurons between distant points in the brain. These vital communication lines are packed beneath the grey matter cortex, much like tightly wound fibers beneath the leather skin of a baseball. White matter in the brain, like white space on paper, is easily dismissed as something defining the areas between the functional components, but recently this naive view has been changing. Unraveling this part of the brain is such a daunting task that only in the last few years have new brain imaging techniques allowed scientists to venture into the white matter realm. As we will see later, these new findings are changing fundamental concepts about how the brain processes and stores information—how we learn. Here inside the blank white regions of brain, glia are the heart of the mechanism.

A revolution in our understanding of how the brain is built, how it functions, how it fails in mental illness and disease, and how it is repaired has been ignited with the recent exploration of these long- neglected brain cells. Glia are the key to understanding this new view of the brain. There is little or no information available about these cells to nonscientists, so we can begin our inquiry with about as much knowl­edge as the pioneering scientists who discovered these various odd brain cells. Since the answers are known to only a few specialists, we can ex­perience the same puzzles, clues, and revelations as the scientists who sleuthed out these peculiar cells in the brain. When these clues are as­sembled, will they reveal another brain working in parallel with our neuronal brain?

Before venturing further, it is essential that we proceed from a common base of knowledge about how the brain operates at the level of cells and circuits. The nervous system works by sending electrical impulses down a wire-like axon at top speeds of 200 miles per hour. Impulses travel through some axons, such as pain fibers, much more slowly—only 2 miles per hour, the pace of our footsteps in a slow walk. This explains the build-up to the full painful sensation when you accidentally hit your thumb with a hammer. The reason for the hundred-fold increase in transmission speed through our high-speed nerve fibers is that they are wrapped with electrical insulation, called myelin. In contrast, pain fibers are uninsulated thread-like axons.

Neurons are not fused to one another like copper wires soldered in a circuit; instead, each neuron in your brain is an island unto itself. Each of these neuronal islands communi­cates by sending a message to another neuron across a tiny gulf of the saltwater that bathes every cell in your body. Because of this gulf of separation, information is not passed on to the next neuron in a circuit by electricity. Instead, the neuron floats chemical messages across the gulf to reach the neuron on the other side. This gulf is the synapse, and the neurons on either side are called presynaptic or postsynaptic neu­rons, depending on whether they are the sending or receiving shore of the gulf. The presynaptic neuron is always the one sending the message from its axon tip; the postsynaptic neuron receives messages across the synapse through its root-like dendrites.

Tysabri Class Action Lawsuit News: News and Information

Tysabri Class Action Lawsuit: The messages are sent in the form of a chemical substance called a neurotransmitter. Microscopic “bottles” inside neurons, called synaptic vesicles, are filled with neurotransmitter molecules. Each synaptic vesi­cle is a tiny sphere too small to see with a light microscope; they are visible only under the high-power magnification of an electron micro­scope. The messages are not floated across the synaptic gulf in these spherical bottles, as you might expect; instead, their contents are dumped into the gulf and diffuse across to the opposite shore. Synaptic vesicles accumulate inside the axon right next to the cell membrane at the tip.

Like cellular water balloons, one or more synaptic vesicles are smashed against the cell membrane of the axon by the force of the electrical im­pulse when it arrives, releasing the vesicles contents into the cellular sea. The neurotransmitter then flows across the synaptic gulf to reach the postsynaptic neuron on the other side.

Sentinel molecules along the shore of the postsynaptic neuron are specially designed to detect the neurotransmitter substance in the syn­aptic gulf. These neurotransmitter receptors are large protein molecules acting as biological nanomachines. In each neurotransmitter receptor there is a passageway that can open into the dendrite of the receiving neuron when neurotransmitter is detected. When the tunnel through the receptor opens briefly, charged ions floating in solution leak out, reducing the voltage inside the postsynaptic neuron. This brief drop in voltage in the postsynaptic neuron is the receiving signal, called the postsynaptic potential. If the synaptic voltage change is big enough, the voltage drop triggers the postsynaptic neuron to fire an impulse out its own axon to signal the next neuron in the circuit. This may seem an awkward way to design a nervous system, but consider the engineering challenge facing Nature: to build a powerful, high-speed biological com­puter using nothing other than cells—tiny bags of saltwater.

So the nerve impulse speeds down an axon, releasing neurotrans­mitter when it reaches the end. The neuro transmitter flows across the synaptic gulf and activates neurotransmitter receptors on the postsyn­aptic neuron, causing a voltage drop in the recipient neuron that will make it fire an electric impulse down its own axon to release neurotrans­mitter onto dendrites of the next neuron in the circuit in relay fashion. To reduce the time it takes for neuro transmitter to diffuse across the syn apse, the gulf of separation is infinitesimally narrow (25 billionths of a meter). The synaptic cleft is so narrow, in fact, it is impossible to see the separation through the most powerful light microscopes. This fact caused decades of controversy in the field of neuroscience until the elec­tron microscope proved that every synapse in the body has a gulf of separation between the pre- and postsynaptic neurons. A message passes across the synapse in about one-tenth of an eye blink, but compared with the two hundred mile per hour speed of the neural impulse, the synapse slows information flow much like a toll booth on a turnpike.

Tysabri Class Action Lawsuit News: Additional Info and News

Tysabri Class Action Lawsuit: When your doctor taps his rubber mallet below your knee to test your knee-jerk reflex, you are seeing a circuit in action that controls the vital coordination crucial for you to walk. Should you stub your toe as you are walking, this misstep will jerk the tendon below your kneecap, just as your doctor does with his mallet. To avoid stumbling, you must now quickly swing your lower leg forward to catch your fall mid-stride. It is vital that this entire sensory-motor reflex is executed in a split sec­ond of time, otherwise you will trip and fall.

To execute this lightning-speed response, there is only one synapse in the entire circuitry controlling the vital reflex that keeps you on your toes. When nerve endings in your kneecap tendon sense a sudden tug from a stubbed toe (or doctor’s mallet), they shoot impulses at two hun­dred miles per hour up the axon from the nerve endings into your spine. There is no time to send signals to your brain; instead, there in your spinal cord a single synapse separates this sensory neuron (bringing information about your leg motion into your spine) from a motor neu­ron that will fire electrical impulses down to your leg muscle to jerk your lower leg forward in a flash—one synapse separating us from falling on our face. (The messages will be relayed by other nerve circuits to your brain, but they arrive after your leg muscles have already responded, and you have no conscious control over what has happened. This is why the doctors mallet triggering the knee-jerk reflex always delights us with surprise as we watch our leg react automatically.)

Synapses do much more than connect neurons; they enable flexibility of information processing. Synapses permit adjustments in functional connections based on experience. The process of learning is more finely regulated than simply making and breaking synapses: the strength of a synaptic connection can be finely tuned in a process called synaptic plas­ticity. How? The molecular changes that strengthen or weaken a synaptic connection are intensely studied by neuroscientists interested in memory and learning, but in principle, the mechanisms are quite simple. Either by releasing a bit more neurotransmitter from the pre-synaptic ending when an impulse arrives, or by adjusting the sensitivity of the postsynaptic neuron receiving the neurotransmitter signal, the same input to a syn­apse can produce greater or lesser voltage change in the postsynaptic neuron, thereby weakening or strengthening the connection.

But there is one additional crucial aspect to this process of synaptic transmission: cleanup. Communication across a synapse would fail if the synaptic gulf were not cleared of n euro transmitter quickly to permit another message to be sent. It was long understood that glia bordering the synaptic cleft carried out this cleanup operation. Protein molecules in the glial membrane pump the neurotransmitter out of the synaptic cleft and into the astrocyte—one of the four major kinds of glial cells— where it is reprocessed. After filtering out the neurotransmitter and re­cycling it into an inert form that cannot be confused as a signal, the astrocyte surrounding a synapse delivers the reprocessed substance back to the presynaptic nerve terminal. The neuron then carries out a simple chemical reaction to convert the inert neurotransmitter back into active neurotransmitter and repackages it into synaptic vesicles.

If neurotransmitter is not taken up efficiently, communication across a synapse will fail because the gulf will become saturated with stale mes­sages. If neurotransmitter is taken up too quickly, the message will ap­pear too briefly to have full effect on the postsynaptic cell. If the energy requirements of the neuron cannot be met by the nutrients supplied by astrocytes, the neuron will run out of gas. Astrocytes are thus in a posi­tion of control.

Our use of the term or terms Tysabri Class Action Lawsuit is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Tysabri Class Action Lawsuit News visit our site often.

Tysabri Class Action

Tysabri Lawyers News – 2/22/2012: Tysabri may be linked to serious negative side effects. If you took Tysabri and believe you suffered negative side effects as a result, contact us today so that we can make arrangements for a free consultation with a law firm that is investigating cases related to the side effects of Tysabri.

Tysabri Lawyers: Like sponges, astrocytes absorb discarded potassium ions from the space around neurons, sucking them into their own cytoplasm. Potas­sium ions are released by neurons when they fire an electrical impulse. Accumulating these excess positive charges inside astrocytes does not create a problem for glial function, because glia do not communicate by firing electrical impulses. Removing the excess potassium is essential for recharging neurons.

How do astrocytes collect and dispose of the excess potassium ions? Astrocytes are connected to one another in avast multicellular network through protein channels called gap junctions. Gap junctions not only couple astrocytes together like snaps on a jacket, they allow potassium to flow freely through the channels and between adjacent glial cells. These gap-junction connections between astrocytes allow them to si­phon off potassium from around a neuron that is actively dumping po­tassium ions as it fires impulses, dispersing the excess positive ions into the network of astrocytes, The community of glial cells, coupled by gap junctions, works cooperatively to maintain the proper potassium ion concentration outside neurons. To dispose of the excess potassium, spe­cialized astrocytes have structures called end feet. These cellular exten­sions grasp small blood vessels like the clinging feet of a bat. Through these end feet, astrocytes dump the accumulated potassium into the bloodstream, as if it were ridding the brain of the waste generated by neuronal activity.

The consequences of glia failing to maintain potassium ions at the proper concentration outside neurons are obvious. During high states of neuronal activity—the extreme being a brain seizure—the potassium concentration builds up around neurons quickly, and its removal by astrocytes is crucial. Without astrocytes sopping up potassium ions, the brain will run out of electrical power. When it is unable to fully recharge its neuronal batteries, the brain waves go flat. In comparison to normal brain waves, these flattened brain waves, called spreading depression, are much like the dim flash of a camera strobe, too feeble to work prop­erly. These depressed waves are seen in EEG recordings accompanying many pathological conditions.

Tysabri Lawyers News: More information about your search

Tysabri Lawyers : Recent research has found that astrocytes markedly change their calcium signaling in animals in which seizures have been induced ex­perimentally. Normally the amount of calcium signaling between astro­cytes in brain cortex is relatively moderate, but after a seizure these astrocytes typically show large oscillations in calcium signals. They sweep through the cortex in strong waves, presumably releasing more glutamate and tipping the brain toward seizure. The evidence suggests that these changes in astrocyte calcium signaling are permanent changes following repeated seizures, rather than echoes in the wake of increased calcium signaling in astrocytes induced during the seizure itself. Possi­bly this change in astrocyte calcium signaling after seizure could be beneficial, but early research suggests that damping the excessive astro­cyte signaling with drugs improves the outcome and limits the death of neurons in animal models of epilepsy.

As mentioned previously, interesting new research reveals that patients with bipolar disorder and schizophrenia also have fewer oligo­dendrocytes, the myelinating cell of the brain. These glial cells wrap axons with myelin, but they are not thought to be involved in glutamate regulation. Nevertheless, too much glutamate can be just as toxic to myelinating glia as it is for neurons. This could be another way glia par­ticipate in mental illness, because when the myelin insulation becomes frayed, so does mental function.

Excess glutamate in the brain may be one of the main causes of death of myelinating glia in the brains of people suffering overproduction of this neurotransmitter. The effects of glutamate on myelinating glia might influence cognitive function even though these cells are not associated with synapses. When one considers that prefrontal lobotomy works by severing the connections to the forebrain, and seeing how the process completely changes a persons personality, it is not difficult to imagine how a pathological loss of myelinating glial cells in these forebrain tracts could lead to psychiatric disorders such as schizophrenia and other mental impairments. Breaking the insulation 011 critical communication cables in the brain will disrupt communication as effectively as severing the cable.

Electroconvulsive shock has a therapeutic effect on clinical depres­sion and schizophrenia by resetting brain waves, but electroconvulsive shock therapy may also activate a beneficial injury response in the brain. Since astrocytes and microglia are the first line of defense in any brain injury, it is obvious why altered glia would be seen in regions of the brain giving rise to seizures. This injury response of glia to brain seizure may also be one of the cellular mechanisms that explains the changed brain function induced by electroshock therapy. Both microg­lia and astrocytes release growth factors in response to brain stress and injury. These growth factors sustain neurons under neurotoxic condi­tions that would normally kill them, and in the healthy brain these glial- derived growth factors promote neuronal growth and health. Both microglia and astrocytes release many different natural inflammatory agents to aid in the healing process, and all of these glial responses prob­ably contribute to the therapeutic effect of electroshock treatment.

Tysabri Lawyers News: Additional Information and Resources

Tysabri Lawyers: This neurovascular unit, as the astrocyte-capillary-neuron group is now called, is also intimately involved in another form of pain and disability suffered by millions of people. Migraines are debilitating vascular head­aches originating within the brain. Electrical impulses spreading to other regions of the brain change nerve cell activity and together with the resulting disturbances in local blood flow cause symptoms that can include visual disturbance, numbness, tingling, and dizziness. This spreading depression of brain waves was described previously in asso­ciation with epilepsy. The same phenomenon occurs in migraine, and here too, astrocytes have a role in the process.

These vascular headaches are caused by blood vessels in the brain dilating excessively and triggering pain and inflammation in the sur­rounding regions. The inflammation triggers the trigeminal nerve, re­sulting in a severe throbbing headache originating in the meninges, the skin-like cells that cover the brain. The senses become hypersensi­tive, so that normal sound and light cause excruciating pain. Nausea, vomiting, loss of appetite, and mood disturbances can accompany mi­graine attacks, and patients often experience auras, visual halos and hallucinations caused by abnormal nerve cell activity in blood-starved cortical regions where vision is processed.

Migraines occur on a periodic basis and they disproportionately affect women. Hormonal effects are thus suspected to have a role in migraine, but it is also in part an inherited disorder. Once we know more about the molecular mechanisms astrocytes use to sense neural activity and control brain waves and local blood flow, new treatments may be devised to control the problem at its source rather than simply trying to blunt the painful aftereffects when the intricate cooperation between neuron, glia, and blood vessel goes awry.

Still, it is surprising that the long-held and well-accepted role of glia as first responders to neuronal injury did not stimulate more vigorous research into exploiting glia for new investigative methods and treat­ments for brain disease and injury. Neuroscientists and the scientific establishment (research funding agencies, editors at scientific journals, and even biomedical companies) were slow to move in this promising direction. Few who marvel at the wondrous new imaging of functional activity in the human brain appreciate that they are seeing the power of glia at work in the brain, both in health and in sickness, as they promote information processing and sustain neuronal function.

Tysabri Lawyers News: News and Information from related Sources

Tysabri Lawyers: People with Ashlyns congenital condition, called CIPA (congenital insensitivity to pain with anhidrosis), usually die before the age of twenty-five. Injury or infection will take them. They have no gag reflex, never feel the tickle to sneeze or the scratchy throat to cough. Never—no matter how severe her injury or what the cause—can Ashlyn tell the doctor where it hurts. Such children are insensible to an inflamed ap­pendix or an ear infection, so the infections rage undetected. As babies they never cry out in pain or develop the alarm and panic reflex at the sight of their own blood. To these babies blood is merely a curiosity. Sadly, grotesquely, but understandably, her own blood was a gruesome plaything for baby Ashlyn. These people, normal in every other respect, suffer painlessly and die prematurely because of a genetic defect that weakens and kills their pain neurons before birth.

In contrast to this puzzle of injury without pain, many people suffer the converse: pain without injury. Chronic pain is not the warning slap of acute pain that saves us from further injury. That pain subsides on its own. Strangely, chronic pain often develops after an injury has healed. It intensifies when there are no longer any noxious or injurious signals to excite pain neurons, yet these neurons scream out in gut-wrenching pain nevertheless. The ceaseless intense pain controls the lives of such chronic sufferers. Pain robs them of sleep and blots out all pleasure from their lives by imposing constant misery. A normally pleasant touch or sensation ignites raging flames of pain. Putting on a pair of socks may be unbearable.

Some patients are forced to accumulate and consume such large quantities of painkillers that the police become suspicious. Doctors who treat patients suffering chronic pain can attract scrutiny from the au­thorities for the high volume of narcotic drugs they must dispense to relieve these patients’ agonies—doses of narcotic drugs that could be fatal for a person without tolerance. At the risk of drawing unwanted attention from police and health insurance companies, many doctors are compelled to limit the dosage of pain medications to levels they know are no longer effective for the patient grown tolerant to them.

With an increasing appreciation of glia in nervous system function, some pain researchers have begun examining the most improbable of suspects, and they have found the culprit. These scientific sleuths were awakened to the improbable realization that the source of chronic pain is not in pain neurons themselves, but rather in glia. This insight is not only leading to new treatments for chronic pain; it is cracking the case of drug addiction to heroin and other narcotics.

Our use of the term or terms Tysabri Lawyers is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Tysabri Lawyers News visit our site often.

Tysabri Lawyers

Tysabri Side Effects News – 2/22/2012: If you were prescribed drug name and have suffered negative side effects, please contact us today so that we can put you in touch with an attorney to advise you of your legal rights.

Tysabri Side Effects: Before considering chronic pain and the role of glia, we need to under­stand some fundamentals of pain circuitry. It may come as a surprise to learn that your pain neurons are not located in your brain. They are not inside your spinal cord either, where you will find the motor neurons that issue commands to your muscles. Pain neurons are squeezed like an afterthought between each vertebra of the bony spinal column that rises as a series of bumps down the center of your back. In the space between each bone in your backbone there is a sack of pain neurons. You have one sack of pain neurons on each side of the spinal column at each seg­ment in your articulated spine.

In four-legged creatures, there is ample room for a small sack of pain neurons stashed between each vertebral joint, but as humans rose up on two hind legs our vertebrae became stacked vertically, compressing the elastic disc of padding between each bone in our backbone. Our spine also became distorted away from the strong arched backbone of other four-legged animals—a horse for example—into a wispy bent S shape, creating kinks at our lower back and neck. These are the vulnerable points for neck and back pain that we humans endure in exchange for trading hooves for hands. Many of us suffer neck and back pain as a result of a herniated or compressed disk squeezing this sack of pain neurons between backbones. This pain is both agonizing and damaging.

The nerve cells inside these sacks are unusual. Their cell bodies are round crystalline globes like gel-filled balloons. Pain neurons have no dendrites, but instead a slender string of an axon extends from each bal­loon and passes, bundled together with strings from other sense neu­rons, through our nerves to reach the skin or muscle somewhere on our bodies. Here the tiny nerve endings fray apart and become specialized into microscopic sensory organs that can sense touch, pressure, heat, cold, irritating chemicals, and substances released by skin cells damaged by sunburn, abrasion or cuts.

Tysabri Side Effects News: More information about your search

Tysabri Side Effects: These nerve sensors also monitor the inside of our bodies. Some of them send their axons into muscle, where their tips spiral around individual muscle fibers, wrapping them like clinging vines. The tiny tendrils feel the stretch and strain of fibers in our muscles. They report back vital information to our unconscious brain on the tension and position of every muscle in our body. Without this delicate and intricate unconscious sensation, we could not move or even stand up balanced on two legs.

Each globular nerve cell also sends another axon into the spinal cord. Thus, sensory neurons have two axons, like two arms, one extend­ing to the periphery where its fingers react to stimulation, and the other penetrating the spinal cord, where it signals what it has detected. The axons penetrate the top (or dorsal surface) of the spinal cord, giving these sensory neurons the name dorsal root ganglion (DRG) neurons. The left and right halves of your body are mirrored, so you have a dorsal root ganglion nerve sack on the left and right sides of your spine be­tween each bump in your backbone.

The axons entering the dorsal surface of your spine then communi­cate through synapses to neurons inside your spinal cord. (The spinal column is your backbone, which shields your spinal cord. The spinal cord is an extension of your brain tissue running like a cord down your back inside these back bones. As mentioned earlier, it is part of your central nervous system, or CNS.) These spinal neurons are linked by a chain of neurons to the opposite side of your spinal cord. Sensations from the right side of your body are channeled across to the left side of your spinal cord, just as commands from the right side of your brain control movement of limbs on the left side of your body. Spinal cord neurons on this side then send axons up to your brain. After reaching the thalamus, the major switch box for information flow into and out of your cerebral cortex, neurons carry the pain signals to your cerebral cortex and to emotional processing centers of your brain, where you perceive the sensation of pain and associate the appropriate emotional reactions with it.

Pain can be stopped by silencing the pain neurons in the skin, as a dentist does when he injects Novocain into your gums. Novocain blocks the ion channels that spark nerve impulses. If there are no nerve im­pulses, no signals of pain will reach the spinal cord, and the tooth can be pulled painlessly. Pain caused by injury is protective, but there is another type of pain that develops mysteriously and intensifies even after the injury has healed. This “neuropathic” pain transforms protective pain into an agonizing disease. Chronic pain develops because of changes in pain circuits in the central nervous system after injury and healing. Neuroscientists know that pain neurons in people suffering chronic pain become hyperexcit- able after healing from injury. The slightest touch or change in tempera­ture sets these neurons firing barrages of nerve impulses that signal intense pain to the brain. The neurons also fire abnormally in bursts of high intensity all on their own. Like a broken record, cycles of nerve impulses scream pain over and over again without any stimulus to trig­ger them.

What causes these pain neurons to spin out of control? After an in­jury to the body or an infection, cells involved in the body’s defense and healing release powerful chemicals called inflammatory cytokines and chemokines. Drugs like ibuprofen and aspirin bring relief by blocking the action of these cytokines. Inflammatory cytokines act in many ways, and one of the consequences for pain fibers is heightened sensitivity. This is natures way of telling us to take it easy until we are healed. We are all familiar with this phenomenon when we feel the region sur­rounding the site of injury become tender and painful. Also, we have all experienced the painful reaction to light and sounds while suffering a severe headache. Our senses become heightened to the point of pain. If the inflammatory condition does not resolve, however, pain and hyper­sensitivity will persist even after the injury has healed.

Tysabri Side Effects News: Additional Information and Resources

Tysabri Side Effects : People suffering chronic pain often describe their misery as raw nerves, but the latest research suggests that chronic pain goes beyond nerve cells. For many pain sufferers, the source of their chronic, un­reachable pain is glia. Linda Watkins, a pain researcher from the Univer­sity of Colorado at Boulder, began to suspect microglia as the source of chronic pain that develops after nerve injury. She recognized that glia have no involvement in transmitting normal pain, but chronicpain that develops after an injury heals might be another matter.

To test this theory that microglia may cause chronic pain, all one must do is block the normal reaction of microglia to injury and then test the animals to see whether numbing the glial response to injury brings relief from chronic pain. Watkins and colleagues conducted tests on rats with chronic pain that had been caused by spinal cord injury. She then administered a drug, minocycline, that targets microglia, preventing their activation and cytokine release in response to injury. Watkins and several other researchers found that injecting this drug into the spinal fluid relieves rats of chronic pain caused by spinal cord injury almost immediately. The experiments proved that the rats receiving the drug experienced greatly reduced chronic pain as a result of blocking micro­glial response to injury.

Other work is extending the findings on microglia and chronic pain to astrocytes by using minocycline. After all, responding to injury and infection is one of the shared functions of astrocytes and microglia. After injury, astrocytes proliferate and begin to express the skeletal pro­tein GFAP at high levels, a cellular remodeling that allows astrocytes to change their shape and motility. Like microglia, astrocytes have many receptors for injury-related signals released by neurons, and in response, astrocytes release growth factors, cytokines, and chemokines that can contribute to chronic pain in some circumstances.

Microglia and astrocytes perform many vital functions after injury, however. Eliminating glial reaction to injury entirely would likely have many undesirable consequences. If we knew more about how microglia sense neural injury and the detailed mechanisms that control their many responses during injury, healing, and development of chronic pain, po­tent new pain medications could be developed to bring relief to chronic pain sufferers without sacrificing the healing functions of glia.

Tysabri Side Effects News: News and Information from related Sources

Tysabri Side Effects: One of the signals damaged nerve cells are known to broadcast when they are in distress is a chemical called fractalkine. This molecule is tethered on the surface of neurons and released like signal flares upon injury or distress. Microglia have special receptors to detect these frac­talkine distress signals. When the sensory receptor proteins on micro­glia sense fractalkines, the glial cells quickly move toward the injury and flood the area with cytokines. This response normally resolves after a period of weeks as the injury heals, but in some unfortunate cases, the microglia do not stop saturating the tissue with cytokines. The injury maybe healed, but the painful injury response continues at full rage.

After administering a drug that dampens the microglial sensors for fractalkine, Watkins and her colleagues tested how sensitive the rat was to pain. There are several well established tests for assessing pain accu­rately and humanely—for example, placing the rat’s tail on a heating pad and turning up the temperature gradually until the rat flicks the tail away. In rats suffering chronic pain as a result of previous nerve injury, even the slightest change in temperature causes the animal to flick its tail away quickly. Other tests using fine bristles of precisely calibrated stiff­ness to touch the skin can accurately gauge sensitivity to pain. Normally these bristles are painless, but in rats (and people) suffering chronic pain the slightest touch becomes excruciatingly painful, like poking an open wound. After researchers treated the rats with the drug blocking the fractalkine receptors on their microglia, the tests showed that the rats were released from the grip of chronic pain. Since the microglia could not receive the fractalkine distress signal sent by injured neurons, they did not release the inflammatory and painful cytokines.

This is an astonishing transition in medical science, for here is a painkiller that does not act on pain neurons; it brings relief from chronic pain by acting on nonneuronal cells. It is as if a door has been cracked open into a room filled with an entirely new stock of drugs to cure chronic pain. Some of these glia-targeted drugs are currently undergo­ing clinical trials in people suffering constant, uncontrollable pain.

Beyond the simple consequence that a small brain with fewer neu­rons and glia will have diminished mental capacity, one need only con­sider the crucial role of glia in orchestrating nervous system development to foresee the multiple devastating consequences of alcohol attacking fetal glia. As we will discuss in the next chapter, glia are the infrastruc­ture of the fetal brain, the scaffolding upon which the fetal nervous system is built. Glia provide trophic factors to promote transformation of immature cells into appropriate types of neurons and sustain those neurons after development. Glia lay down molecules in tracts to guide axons to form appropriate connections that will make functional cir­cuits. Glia promote the formation of synapses. Glia take up neuro­transmitters and maintain the vital salt and nutrient concentration surrounding neurons at the proper levels. Glia protect the brain from infection. Glia control migration of cells during development The loss of glia poisoned by alcohol will have a multitude of negative conse­quences on the developing brain.

Our use of the term or terms Tysabri Side Effects is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Tysabri Side Effects News visit our site often.

Tysabri Side Effects